Podcasts about imugene

MARKET WRAP: ASX200: down 0.41% to 7,828 GOLD: $3,047 US/oz BITCOIN: $131,457 AUD A board review into the conduct of Wisetech Global founder Richard White saw shares fall yet again, down 2.3% to $82.81. A hit to the sales of Myer saw first-half profits down more than 18% to $42.4 million. Shares finished 1.3% lower. Mineral Resources slipped just under 4% after a road train crash halted its iron ore haulage. Coal miner New Hope had another good day off the back of its first half results, gaining another 4.2% to $4.20. FDA approval for an Imugene product helped its shares to rocket 14.3%. The insurers gained ground with QBE up 4.1%, Suncorp 1.7% higher, and IAG rising 1.5%. CURRENCY UPDATE: AUD/USD: 63.44 US cents AUD/GBP: 48.9 pence AUD/EUR: 58 Euro cents AUD/JPY: 94 Japanese yen AUD/NZD: 1.09 NZ dollars See omnystudio.com/listener for privacy information.

Wisetech Global has given a slap on the wrist to Richard White over his conduct. Is the founder now invincible? MARKET WRAP: ASX200: down 0.41% to 7,828 GOLD: $3,047 US/oz BITCOIN: $131,457 AUD A board review into the conduct of Wisetech Global founder Richard White saw shares fall yet again, down 2.3% to $82.81. A hit to the sales of Myer saw first-half profits down more than 18% to $42.4 million. Shares finished 1.3% lower. Mineral Resources slipped just under 4% after a road train crash halted its iron ore haulage. Coal miner New Hope had another good day off the back of its first half results, gaining another 4.2% to $4.20. FDA approval for an Imugene product helped its shares to rocket 14.3%. The insurers gained ground with QBE up 4.1%, Suncorp 1.7% higher, and IAG rising 1.5%. CURRENCY UPDATE: AUD/USD: 63.44 US cents AUD/GBP: 48.9 pence AUD/EUR: 58 Euro cents AUD/JPY: 94 Japanese yen AUD/NZD: 1.09 NZ dollars See omnystudio.com/listener for privacy information.

Imugene Ltd CEO Leslie Chong talked with Kerry Stevenson at Proactive about the FDA's fast-track designation for its immunotherapy candidate, Azercell. The therapy, an allogeneic off-the-shelf CAR-T treatment, has shown promising results in patients with diffuse large B-cell lymphoma (DLBCL), a highly aggressive form of blood cancer. Chong highlighted that four out of seven patients treated with Azercell achieved complete response, meaning their cancer was no longer detectable. The longest response duration has now exceeded 11 months. “The FDA has recognised the importance of a product like this and has given us fast-track designation,” Chong stated. The FDA's fast-track status allows Imugene to expedite regulatory discussions and move towards potential commercialization more efficiently. The company sees this as a critical milestone, with Chong emphasising that the priority now is gathering sufficient data to advance towards registration studies. With an estimated 80,000 new DLBCL cases diagnosed annually in the US, Azercell could address a significant unmet need, especially for patients who have exhausted other treatment options. For more updates on Imugene and other biotech innovations, visit Proactive's YouTube channel. Don't forget to like this video, subscribe, and enable notifications for future content. #Imugene #Biotech #CancerResearch #FDA #CAR_T #Oncology #BloodCancer #DLBCL #MedicalBreakthrough #FastTrack #Immunotherapy

Imugene Ltd (ASX: IMU, OTC: IUGNF) chief medical officer Dr. Paul Woodard and managing director and CEO Leslie Chong talked with Proactive's Tylah Tully about the latest results from the Phase 1b clinical trial of Azer-cel, the company's CD19 CAR-T therapy. Dr. Woodard, speaking from 2025 Tandem Meetings in Honolulu, shared the excitement around the trial's findings. Azer-cel is being developed for patients who have relapsed after multiple lines of treatment. The latest data reveals a 57% complete response rate, meaning no detectable lymphoma in these patients. Chong highlighted that the addition of a low dose of IL-2 to Azer-cel has contributed to T-cell proliferation, helping patients' immune systems fight back. She emphasised that seeing durable responses in patients who have exhausted multiple treatment options is a significant achievement. Dr. Woodard also underscored the importance of these results, stating that some patients are experiencing long-lasting remissions, with one individual remaining in complete remission for over ten months. These findings reinforce the potential of Azer-cel in addressing an unmet need in relapsed and refractory lymphoma patients. #Imugene #AzerCel #CAR_T #Biotech #Oncology #CancerResearch #ClinicalTrials #Lymphoma #MedicalBreakthrough #Investing

Imugene Ltd chief operating officer Brad Glover and managing director and CEO Leslie Chong talked with Proactive's Tylah Tully about the company's latest Appendix 4C quarterly report, which provided several key updates for shareholders and investors. The pair also discussed the recent $20 million received from CVI Investments, ongoing clinical trials and financial outlook for 2025. Chong provided updates on Imugene's metastatic advanced solid tumour study (MARS), highlighting that a cholangiocarcinoma patient has been in full remission for over two years. She also shared news on the company securing a patent for its CF33 oncolytic virus technology, which extends until 2040. Glover discussed progress in Imugene's oncolytic virus program, stating that the company has initiated a combination trial with a CD19-targeting bispecific antibody. He also detailed the expansion of the Azer-cel trial, noting that the first Australian site has opened, and initial results from US sites have been promising. Financially, Chong reported that Imugene has approximately $65.4 million in cash, ensuring funding through 2025. Looking ahead, Glover emphasised the company's focus on clinical execution and data generation in 2025. #Imugene #CancerResearch #Biotech #ClinicalTrials #OncolyticVirus #Immunotherapy #StockMarket #ASX #MedicalInnovation

Imugene Ltd (ASX:IMU, OTC:IUGNF) CEO Leslie Chong and Professor Yuman Fong, chair of the Department of Surgery at the City of Hope and strategic advisor to Imugene, spoke with Proactive's Tylah Tully about the latest developments in Imugene's CF33 MAST (Metastatic Advanced Solid Tumours) VAXINIA study. Professor Fong, the inventor of CF33, described the approach behind the therapy, where genetically engineered viruses are designed to infect and kill cancer cells without harming normal cells. “In our lab, we prioritized creating a virus that could kill cancer of various types while remaining safe for humans,” he noted, explaining that this latest generation of the CF33 virus has shown positive results across a broad range of cancers, including melanoma and bile duct cancer. Chong and Professor Fong discussed the ongoing trials, where Imugene has received FDA orphan drug status and is seeing promising tumour responses in patients with advanced-stage cancers, including the challenging bile duct cancer. Chong highlighted the stability achieved in patients participating in the trial, some of whom previously exhausted other treatments. She explained, “Even at low doses, we're seeing disease stabilization, which is remarkable given that these patients have been through multiple other therapies before coming to us.” As CF33's clinical trials continue, Chong and Professor Fong are optimistic about the potential to offer a new option for patients with difficult-to-treat cancers. With the backing of a strong clinical and manufacturing team, Imugene is now expanding the trial to additional patients and combining CF33 with CD19-targeting drugs to further evaluate its impact on immune response and tumor reduction. #ProactiveInvestors #Imugene #ASX #CancerResearch #CF33 #OncolyticVirus #CancerTreatment #VAXINIA #ClinicalTrials #Immunotherapy #CancerInnovation #MetastaticCancer #ProactiveUpdates #LeslieChong #YumanFong #FDAApproval #OrphanDrugStatus #CancerScience

Imugene Ltd (ASX:IMU, OTC:IUGNF) managing director and CEO Leslie Chong joins Proactive's Tylah Tully to provide a company update, including launching the first Australian site for the Phase 1b clinical trial of its azer-cel (azercabtagene zapreleucel) allogeneic CAR T-cell therapy. The Royal Prince Alfred Hospital in Sydney will lead Australian patient recruitment, with enrolment beginning in November 2024, marking Australia's only active trial for allogeneic CAR T-cell therapy in treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This Australian expansion offers patients access to azer-cel, addressing critical treatment gaps for DLBCL, an aggressive form of non-Hodgkin's lymphoma. Chong emphasised the importance of local access to this innovative therapy. Imugene's US trials have shown promising results, with three patients achieving complete responses, two of whom received a combination of azer-cel with lymphodepletion and interleukin-2 (IL-2), showing durable responses extending beyond 90 and 120 days. The company has also dosed the first patient in the intratumoural (IT) injection combination arm of its OASIS Phase 1 clinical trial for onCARlytics (CF33-CD19). This trial aims to test the efficacy and safety of Imugene's CD19-expressing oncolytic virotherapy in advanced or metastatic solid tumours. The first colorectal cancer patient was treated at Northwestern University, and the trial is expected to enrol up to 40 participants with various advanced cancers. #ProactiveInvestors #Imugene #ASX  #Oncology #CAR_TCellTherapy #AzerCel #Vaxinia #ClinicalTrials #CancerResearch #Immunotherapy #DLBCL #HER2 #BileCancer #Biotechnology #ASX #FDAApproval #OrphanDrug #FastTrack #BiotechInvesting #OncolyticVirotherapy #CancerTreatment #CashPosition

Imugene Ltd (ASX:IMU) managing director and CEO Leslie Chong joins Proactive's Tylah Tully to discuss the company's latest update. A bile tract cancer patient in its Phase 1 MAST (Metastatic Advanced Solid Tumours) trial has maintained a complete response (CR) for over two years. The MAST study is assessing the safety and efficacy of Imugene's oncolytic virotherapy, CF33-hNIS (VAXINIA), designed to target and destroy cancer cells. The bile tract cancer expansion of the trial recently also cleared its first patient cohort, with no dose-limiting toxicities observed, and enrolment is now open for up to 10 additional patients. VAXINIA has received both FDA Fast Track Designation (November 2023) and Orphan Drug Designation (September 2024) for treating bile tract cancer, supporting faster regulatory pathways and potential incentives such as market exclusivity upon approval. Additionally, Imugene's intellectual property around CF33 received a US patent extension to 2040, covering both VAXINIA and CHECKVacc variants, reinforcing its presence in the US oncology market. Chong highlighted the patient's prolonged response and the importance of the recent patent extension in strengthening Imugene's position in the core healthcare market. The company continues to recruit patients for the bile tract cancer segment of the trial. #ProactiveInvetstors #Imugene #ASX #CancerResearch #Oncology #BileTractCancer #MASTTrial #VAXINIA #CF33Virus #ClinicalTrial #FDAFastTrack #OrphanDrugDesignation #PatentExtension #CancerTreatment #OncolyticVirus #Immunotherapy #MedicalBreakthrough #CancerSurvivorship #USHealthcare #DrugDevelopment #CancerInnovation #Biotechnology

The US market closed lower on Wednesday despite the Fed announcing a 50-basis point rate cut in the first rate cut of the interest rate cycle as inflation continues to ease in the world's largest economy. The Dow Jones fell 0.25% on Wednesday while the S&P500 lost 0.35 and the tech-heavy Nasdaq ended the day down 0.31%. Investors likely responded to the 50-basis point rate cut with concerns over the Fed potentially cutting aggressively in fear of further weakening to the US economy in the months to come.Over in Europe on Wednesday, markets closed lower as investors assessed key economic data released in the region. The STOXX 600 fell 0.5%, Germany's DAX lost 0.08%, the French CAC fell 0.57% and, in the UK, the FTSE100 ended the day down 0.68%. UK inflation data for August was released yesterday with a flat reading on July of 2.2%, which comes ahead of the Bank of England's rate decision on Thursday UK time where it is expected the BoE will maintain the current cash rate of 5% for another period.The Asia region closed mostly higher on Wednesday as investors in the region digested key economic data including Japan's exports and imports rising 5.6% and 2.3% respectively in August and the country's trade deficit easing over the month. Japan's Nikkei rose 0.5% on Wednesday while China's CSI index rose 0.37% and South Korea and Hong Kong's markets were closed for a holiday.Locally on Wednesday, the ASX 200 ended the midweek session flat after setting a fresh record close on Tuesday as a decline in the price of iron ore hit the big miners.Underwhelming economic data out of China over the weekend placed further pressure on the iron ore price as the world's second largest economy continues its struggle to regain economic expansion and stability post pandemic.Rio Tinto and BHP each fell just shy of 1%, while FMG ended the day down 0.3%.Harvey Norman shares closed flat on Wednesday despite the homewares retailer being hit with a class action accusing the retailer of allegedly selling hundreds of millions of dollars of unnecessary and worthless extended warranties. Harvey Norman said it complied with all relevant laws.Biotech company Imugene received a long-awaited Orphan Drug Designation from the FDA for its CF33-hNIS vaxinia to treat cholangiocarcinoma (COLAN-GIO-CARCINOMA) which is a rare form of bile tract cancer. Shares in the company rose 6.25% yesterday.What to watch today:All eyes locally today will be on Australia's latest jobs data which is out this morning with the market expecting the unemployment rate to remain flat at 4.2% while it is forecast that the employment change is expected to drop to an increase of just 28,000 in August from the high jump of 58.2k reported in July.Ahead of Thursday's trading session the SPI futures are anticipating the ASX to open the new trading day down half a percent tracking Wall Street's loss overnight.On the commodities front this morning oil is trading 1.66% lower at US$70/barrel, gold is down 0.6% at US$2558.84/ounce, and iron ore is up 0.04% at US$91.98/tonne.The Aussie dollar has strengthened overnight to buy 67.65 US cents, 96.13 Japanese Yen, 51.23 British Pence and 1 New Zealand dollar and 9 cents.Trading Ideas:Bell Potter has initiated coverage of Genesis Minerals (ASX:GMD) with a buy rating and a 12-month price target of $2.55/share. Genesis Minerals is a Western Australian gold production and development company focused on the Leonora District with two gold processing plants and four mining centres under the company's belt as well as two critical deposits boasting high grade gold. The company's value is in its 10-year long-term growth plan and the restart of the Laverton plant in December 2024.Trading Central has identified a bullish signal on Adairs (ASX:ADH) following the formation of a pattern over a period of 17-days which is roughl

Imugene Ltd (ASX: IMU) chief operating officer Brad Glover and CEO Leslie Chong sit down with Proactive's Tylah Tully to discuss positive results from its Phase 1b clinical trial of azer-cel (azercabtagene zapreleucel), an allogeneic off-the-shelf CD19 CAR T therapy, in patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL). This trial addresses a significant unmet need as all participants had cancer that returned after autologous CAR T therapy. Ten patients have been treated, divided into two cohorts. Cohort A involved six patients treated with azer-cel and lymphodepletion chemotherapy. Cohort B included four patients who received azer-cel, lymphodepletion chemotherapy, and interleukin 2 (IL-2). Results showed three complete responses, with two in Cohort B and one in Cohort A. The complete responses in Cohort B have been durable, with one exceeding 120 days and another more than 90 days. All four patients in Cohort B remain in the trial, and more patients will be enrolled. The treatment has been safe and tolerable. The promising results from Cohort B will be included in the potential FDA Phase 2/3 registration package. Imugene plans to continue patient enrolment and further explore the therapy's potential, including future studies combining azer-cel with its onCARlytics program for solid tumours. #ProactiveInvestors #Imugene #ASX #ClinicalTrial #AzerCel #CAR_T #DLBCL #NonHodgkinsLymphoma #CancerResearch #Oncology #FDAApproval #MedicalResearch #BloodCancer #LymphomaTreatment #Biotechnology #Immunotherapy #Phase1b #CompleteResponse #PatientCare #MedicalBreakthrough #SolidTumors #OnCARlytics #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

With Stake, Australia's leading investing platform, I'm excited to share the 12th episode of 'Going Public' - a monthly series giving you unique access to the entrepreneurs, founders and executives who've taken their business public.In this episode of the Going Public series, Mark learns about the remarkable journey of Imugene Ltd (ASX: IMU), a clinical-stage immuno-oncology company revolutionising cancer treatment with cutting-edge immunotherapies. Join us as we explore how CEO Leslie Chong has helped transform Imugene from a single-technology startup to a biotech leader with five active clinical trials targeting various cancers. Discover the strategic moves that propelled the company's market cap from $10 million to $500 million and secured its place in the ASX Top 300. We'll also hear from Executive Chairman Paul Hopper, the mastermind behind the IMU listing and successful IPOs for Radiopharm (RAD) and Chimeric (CHM). This episode offers invaluable insights into the world of biotech, innovation, and the path to IPO success.DISCLAIMER:Views expressed are those of the individual only. This does not constitute financial advice. You can subscribe to the newsletter here: https://lnkd.in/e7C8akgj. Join the Facebook Group.Follow Mark Bouris on Instagram, LinkedIn & YouTube. See omnystudio.com/listener for privacy information. Hosted on Acast. See acast.com/privacy for more information.

Imugene Ltd (ASX:IMU, OTC:IUGNF) managing director and CEO Leslie Chong and strategic advisor Dr Yuman Fong sit down with Proactive's Jonathan Jackson to discuss Professor Fong's expertise and the latest company developments. Dr Fong is a world-renowned cancer researcher, physician and surgeon whose clinical work has focused on OV for more than 30 years. He is the inventor of OV CF33. Imugene has dosed the first patient in its trial for bile tract cancer (cholangiocarcinoma) patients. The MAST (metastatic advanced solid tumours) Phase 1 trial has been expanded due to early responses in gastrointestinal cancers, particularly cholangiocarcinoma, using Imugene's cancer-killing virus CF33, known as VAXINIA. The trial, held at St Vincent's Hospital, Melbourne, Australia, expects to enrol 10 patients. Interim results showed positive responses in gastrointestinal cancers, including a complete response in bile tract cancer. The trial's fifth cohort of both arms has cleared and the sixth high-dose cohort is now open. Chong expressed optimism about VAXINIA's potential in bile tract cancer, highlighting the trial's advancement to higher doses to gather key data. In November 2023, the US FDA granted fast-track designation to VAXINIA MAST for bile tract cancer, enabling closer cooperation to expedite the approval process. Bile tract cancer is a rare and challenging disease, often responding poorly to immunotherapy. A recent study reported a complete response in a patient after receiving a mid-dose of IT-administered VAXINIA monotherapy, with no safety signals observed. The Phase 1 MAST trial has progressed through monotherapy dose escalation cohorts and includes a combination study with pembrolizumab. The CF33 virus, developed by City of Hope, has shown preclinical effectiveness in shrinking various cancer tumours. #ProactiveInvestors #Imugene #ASX #OTC #CancerResearch, #BileTractCancer, #Cholangiocarcinoma, #VAXINIA, #Oncology, #ClinicalTrial, #MASTTrial, #FDAFastTrack, #InnovativeTreatment, #GastrointestinalCancer, #CancerTreatment, #LeslieChong, #StVincentsHospital, #Melbourne, #Immunotherapy, #CheckpointInhibitor, #Pembrolizumab, #CF33Virus, #CityOfHope #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Australia's medical technology research and development has always been world-leading, and a new way of treating bile tract cancer could be the next big breakthrough.See omnystudio.com/listener for privacy information.

Imugene Ltd (ASX:IMU OTCMKTS:IUGNF) CEO Leslie Chong sits down with Proactive's Jonathan Jackson after the company dosed the first patient in the intravenous (IV) infusion combination arm of its Phase 1 onCARlytics trial. The patient, diagnosed with cholangiocarcinoma, received treatment at City of Hope in California. Imugene's OASIS trial is the first to combine a CD19-expressing oncolytic virus with a CD19-targeting drug. Chong stated that the enrolment of the first IV combination patient advanced the OASIS trial, which integrated their CD19 oncolytic virus with the CD19 bispecific drug, blinatumomab (Blincyto®), in patients with advanced solid cancers. The Phase 1 trial aims to evaluate the safety and efficacy of onCARlytics (CF33-CD19) administered via intratumoural (IT) injection or IV infusion. The treatment may be given alone or with blinatumomab. Currently, the trial is being conducted at City of Hope, University of Cincinnati, and MD Anderson Cancer Center, with plans to expand to 10 sites to recruit 40-45 patients with advanced solid cancers. The primary objective is to assess the safety and efficacy of onCARlytics via IT or IV routes, as monotherapy or in combination with blinatumomab. The trial began dosing its first IV monotherapy patient with bile tract cancer in February, with early combination data expected by Q4 2024. CD19 is a significant target for blood cancers, representing about 10% of all cancers. However, solid cancers lack a common surface target. onCARlytics aims to convert solid tumours into CD19-expressing tumours, making them treatable with CD19-targeting therapies. If successful, this approach could extend CD19 therapies to 90% of the cancer market, valued at US$532 billion by 2032. #ProactiveInvestors #Imugene #ASX #CancerTreatment #onCARlytics #CD19Therapy #Cholangiocarcinoma #OASISTrial #ClinicalTrials #Biotech #CancerResearch #Immunotherapy #Oncology #MedicalResearch #HealthNews #CityOfHope #Blincyto #Blinatumomab #SolidTumours #CancerCare #MedicalInnovation #USHealthcare #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Imugene Ltd (ASX:IMU) managing director and CEO Leslie Chong sits down with Proactive's Jonathan Jackson to discuss the strategic partnership the company has formed with Kincell Bio, LLC that involves the sale of Imugene's Current Good Manufacturing Practice (CGMP) compliant cell therapy manufacturing facility in North Carolina. This agreement is set to bolster both companies' positions in the immunocellular therapy market. Kincell Bio will acquire the facility with a total investment of up to US$6 million, which includes upfront and milestone-driven payments over the next three years. This acquisition will enable Kincell Bio to expand its manufacturing capacity and continue providing high-quality development and manufacturing support. As part of the deal, Imugene will transfer process and analytical development activities of its Azer-cel to Kincell Bio, streamlining operations and focusing on clinical supply for ongoing trials. This move is expected to bring substantial financial efficiencies for Imugene, with anticipated savings of US$32 million in staff costs, manufacturing efficiencies and overheads over three years. Additionally, the restructuring will result in a 50% reduction in staff but extend Imugene's cash runway to 2026. Chong explains the implications of this partnership and how it benefits upcoming inflection points. #ProactiveInvestors #Imugene #ASX #Biotech #Azer-cel #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Imugene Ltd (ASX:IMU) CEO Leslie Chong sits down with Proactive's Jonathan Jackson to discuss enrolment for a pivotal expansion study targeting bile tract cancer (cholangiocarcinoma) patients. This follows the successful completion of the fifth high-dose cohort in the intratumoural arm of the VAXINIA monotherapy dose escalation study, which evaluates the effectiveness of the cancer-killing virus CF33-hNIS (VAXINIA). Chong gives insight into the new phase of the study, particularly given VAXINIA's promising results in gastrointestinal cancers. Notably, the trial has already seen remarkable outcomes, including one patient with cholangiocarcinoma achieving a complete response and another maintaining stable disease. The expansion trial, known as the MAST trial, aims to enrol 10 patients and is part of Imugene's broader efforts to advance its innovative oncological treatments. Previous phases have demonstrated significant positive responses, especially in gastrointestinal cancers, further underscoring the potential of VAXINIA. Additionally, this week, Imugene will present VAXINIA at the 2024 Cholangiocarcinoma Foundation Annual Conference. The company continues to gather support for its cutting-edge therapies, which have so far shown no safety concerns across various cancer types, including thymic carcinoma and triple-negative breast cancer. #ProactiveInvestors #Imugene #ASX #Biotech #gastrointestinalcancer #VAXINIA #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Imugene Ltd (ASX:IMU) CEO Leslie Chong joins Proactive's Jonathan Jackson in the Proactive studio to discuss how the company has advanced its Phase 1 onCARlytics solid tumour trial to combination arm treatment. The trial, known as OASIS, focuses on adult patients with advanced or metastatic solid tumours, aiming to assess the safety and efficacy of intratumoural (IT) injection and intravenous (IV) infusion, alone or combined with the CD19 targeting drug blinatumomab (Blincyto® by Amgen). The Cohort Review Committee (CRC) has reported no safety issues in the onCARlytics monotherapy lead-in study, prompting the clearance of the first cohort and the initiation of the combination arm. The OASIS trial represents a pioneering approach in solid tumour treatment, combining a CD19-expressing oncolytic virus to prime tumours for attack by CD19-targeting therapeutics. The trial's potential to shift the paradigm in solid tumour treatment is underlined by the promising advancements, with the combination arm set to explore the efficacy of onCARlytics in conjunction with blinatumomab. Imugene's progress in the OASIS trial signals a significant step forward in advancing novel immunotherapies for solid tumour patients. #ProactiveInvestors #Imugene #ASX #biotech #onCARlytics #solidtumourtreatment #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GUS865. CME/MOC/AAPA/IPCE credit will be available until February 18, 2025.Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported through independent educational grants from AstraZeneca and Incyte Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerMilind Javle, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals Inc.; Array BioPharma Inc.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; BeiGene; Biocartis; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; EMD Serono Inc.; GlaxoSmithKline; Halozyme Therapeutics; Helsinn; Incyte Corporation; Ipsen; Janssen Pharmaceuticals, Inc.; Lilly; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; OncoSil Medical Ltd; QED Therapeutics, Inc.; Servier Laboratories; Taiho Oncology, Inc.; and TransThera Biosciences Co. Ltd.Faculty/PlannerTanios Bekaii-Saab, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for (to self) AbbVie; Artiva Biotherapeutics; Aptitude Health; AstraZeneca; BeiGene; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Caladrius Biosciences; Celularity Inc.; Daiichi Sankyo Co., Ltd.; Deciphera Pharmaceuticals, Inc.; Exact Sciences Corporation; Exelixis, Inc.; Foundation Medicine, Inc.; GlaxoSmithKline; Immuneering Corporation; Illumina, Inc.; Imugene Ltd.; Janssen Pharmaceuticals, Inc.; KANAPH Therapeutics Inc.; Natera, Inc.; Replimune Group Inc.; Sanofi; Sobi; Stemline Therapeutics, Inc.; Treos Bio Limited; Xilis, Inc; and Zai Lab. To institution: Arcus Biosciences, Inc.; Bayer Corporation; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; Merck KGaA; Merus; Pfizer; Seattle Genetics; and Servier Laboratories.Grant/Research Support from AbGenomics Corporation; Agios Pharmaceuticals, Inc.; Arcus Biosciences, Inc.; Arys; Atreca, Inc.; Bayer Corporation; Boston Biomedical Inc.; Bristol Myers Squibb; Celgene Corporation; Clovis Oncology; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Lilly; Merus N.V.; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Seattle Genetics. Research funding to Institution.Data Safety Monitoring Board for 1Globe Health Institute; AstraZeneca; Exelixis, Inc.; FibroGen, Inc.; Lilly; Merck & Co., Inc./Eisai Co., Ltd.; Pancreatic Cancer Action Network; Suzhou Kintor Pharmaceuticals, Inc.; and The Valley Hospital.Other Financial or Material Support from holding patents WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to Imugene. WO/2019/055687 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA – Licensed to Recursion.Faculty/PlannerRachna Shroff, MD, MS, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Genentech, Inc.; Incyte Corporation; Merck & Co., Inc.; QED Therapeutics; Servier Laboratories; Syros Pharmaceuticals, Inc.; and Zymeworks Inc.Grant/Research Support from Bayer; Bristol Myers Squibb; Exelixis, Inc.; IMV Inc.; Loxo Oncology, Inc.; Merck & Co., Inc.; Novocure, Inc.; NuCana; Pieris Pharmaceuticals, Inc.; QED Therapeutics; Rafael Pharmaceuticals, Inc.; Seagen; and Taiho Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GUS865. CME/MOC/AAPA/IPCE credit will be available until February 18, 2025.Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported through independent educational grants from AstraZeneca and Incyte Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerMilind Javle, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals Inc.; Array BioPharma Inc.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; BeiGene; Biocartis; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; EMD Serono Inc.; GlaxoSmithKline; Halozyme Therapeutics; Helsinn; Incyte Corporation; Ipsen; Janssen Pharmaceuticals, Inc.; Lilly; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; OncoSil Medical Ltd; QED Therapeutics, Inc.; Servier Laboratories; Taiho Oncology, Inc.; and TransThera Biosciences Co. Ltd.Faculty/PlannerTanios Bekaii-Saab, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for (to self) AbbVie; Artiva Biotherapeutics; Aptitude Health; AstraZeneca; BeiGene; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Caladrius Biosciences; Celularity Inc.; Daiichi Sankyo Co., Ltd.; Deciphera Pharmaceuticals, Inc.; Exact Sciences Corporation; Exelixis, Inc.; Foundation Medicine, Inc.; GlaxoSmithKline; Immuneering Corporation; Illumina, Inc.; Imugene Ltd.; Janssen Pharmaceuticals, Inc.; KANAPH Therapeutics Inc.; Natera, Inc.; Replimune Group Inc.; Sanofi; Sobi; Stemline Therapeutics, Inc.; Treos Bio Limited; Xilis, Inc; and Zai Lab. To institution: Arcus Biosciences, Inc.; Bayer Corporation; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; Merck KGaA; Merus; Pfizer; Seattle Genetics; and Servier Laboratories.Grant/Research Support from AbGenomics Corporation; Agios Pharmaceuticals, Inc.; Arcus Biosciences, Inc.; Arys; Atreca, Inc.; Bayer Corporation; Boston Biomedical Inc.; Bristol Myers Squibb; Celgene Corporation; Clovis Oncology; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Lilly; Merus N.V.; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Seattle Genetics. Research funding to Institution.Data Safety Monitoring Board for 1Globe Health Institute; AstraZeneca; Exelixis, Inc.; FibroGen, Inc.; Lilly; Merck & Co., Inc./Eisai Co., Ltd.; Pancreatic Cancer Action Network; Suzhou Kintor Pharmaceuticals, Inc.; and The Valley Hospital.Other Financial or Material Support from holding patents WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to Imugene. WO/2019/055687 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA – Licensed to Recursion.Faculty/PlannerRachna Shroff, MD, MS, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Genentech, Inc.; Incyte Corporation; Merck & Co., Inc.; QED Therapeutics; Servier Laboratories; Syros Pharmaceuticals, Inc.; and Zymeworks Inc.Grant/Research Support from Bayer; Bristol Myers Squibb; Exelixis, Inc.; IMV Inc.; Loxo Oncology, Inc.; Merck & Co., Inc.; Novocure, Inc.; NuCana; Pieris Pharmaceuticals, Inc.; QED Therapeutics; Rafael Pharmaceuticals, Inc.; Seagen; and Taiho Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GUS865. CME/MOC/AAPA/IPCE credit will be available until February 18, 2025.Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported through independent educational grants from AstraZeneca and Incyte Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerMilind Javle, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals Inc.; Array BioPharma Inc.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; BeiGene; Biocartis; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; EMD Serono Inc.; GlaxoSmithKline; Halozyme Therapeutics; Helsinn; Incyte Corporation; Ipsen; Janssen Pharmaceuticals, Inc.; Lilly; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; OncoSil Medical Ltd; QED Therapeutics, Inc.; Servier Laboratories; Taiho Oncology, Inc.; and TransThera Biosciences Co. Ltd.Faculty/PlannerTanios Bekaii-Saab, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for (to self) AbbVie; Artiva Biotherapeutics; Aptitude Health; AstraZeneca; BeiGene; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Caladrius Biosciences; Celularity Inc.; Daiichi Sankyo Co., Ltd.; Deciphera Pharmaceuticals, Inc.; Exact Sciences Corporation; Exelixis, Inc.; Foundation Medicine, Inc.; GlaxoSmithKline; Immuneering Corporation; Illumina, Inc.; Imugene Ltd.; Janssen Pharmaceuticals, Inc.; KANAPH Therapeutics Inc.; Natera, Inc.; Replimune Group Inc.; Sanofi; Sobi; Stemline Therapeutics, Inc.; Treos Bio Limited; Xilis, Inc; and Zai Lab. To institution: Arcus Biosciences, Inc.; Bayer Corporation; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; Merck KGaA; Merus; Pfizer; Seattle Genetics; and Servier Laboratories.Grant/Research Support from AbGenomics Corporation; Agios Pharmaceuticals, Inc.; Arcus Biosciences, Inc.; Arys; Atreca, Inc.; Bayer Corporation; Boston Biomedical Inc.; Bristol Myers Squibb; Celgene Corporation; Clovis Oncology; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Lilly; Merus N.V.; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Seattle Genetics. Research funding to Institution.Data Safety Monitoring Board for 1Globe Health Institute; AstraZeneca; Exelixis, Inc.; FibroGen, Inc.; Lilly; Merck & Co., Inc./Eisai Co., Ltd.; Pancreatic Cancer Action Network; Suzhou Kintor Pharmaceuticals, Inc.; and The Valley Hospital.Other Financial or Material Support from holding patents WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to Imugene. WO/2019/055687 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA – Licensed to Recursion.Faculty/PlannerRachna Shroff, MD, MS, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Genentech, Inc.; Incyte Corporation; Merck & Co., Inc.; QED Therapeutics; Servier Laboratories; Syros Pharmaceuticals, Inc.; and Zymeworks Inc.Grant/Research Support from Bayer; Bristol Myers Squibb; Exelixis, Inc.; IMV Inc.; Loxo Oncology, Inc.; Merck & Co., Inc.; Novocure, Inc.; NuCana; Pieris Pharmaceuticals, Inc.; QED Therapeutics; Rafael Pharmaceuticals, Inc.; Seagen; and Taiho Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GUS865. CME/MOC/AAPA/IPCE credit will be available until February 18, 2025.Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported through independent educational grants from AstraZeneca and Incyte Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerMilind Javle, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals Inc.; Array BioPharma Inc.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; BeiGene; Biocartis; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; EMD Serono Inc.; GlaxoSmithKline; Halozyme Therapeutics; Helsinn; Incyte Corporation; Ipsen; Janssen Pharmaceuticals, Inc.; Lilly; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; OncoSil Medical Ltd; QED Therapeutics, Inc.; Servier Laboratories; Taiho Oncology, Inc.; and TransThera Biosciences Co. Ltd.Faculty/PlannerTanios Bekaii-Saab, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for (to self) AbbVie; Artiva Biotherapeutics; Aptitude Health; AstraZeneca; BeiGene; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Caladrius Biosciences; Celularity Inc.; Daiichi Sankyo Co., Ltd.; Deciphera Pharmaceuticals, Inc.; Exact Sciences Corporation; Exelixis, Inc.; Foundation Medicine, Inc.; GlaxoSmithKline; Immuneering Corporation; Illumina, Inc.; Imugene Ltd.; Janssen Pharmaceuticals, Inc.; KANAPH Therapeutics Inc.; Natera, Inc.; Replimune Group Inc.; Sanofi; Sobi; Stemline Therapeutics, Inc.; Treos Bio Limited; Xilis, Inc; and Zai Lab. To institution: Arcus Biosciences, Inc.; Bayer Corporation; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; Merck KGaA; Merus; Pfizer; Seattle Genetics; and Servier Laboratories.Grant/Research Support from AbGenomics Corporation; Agios Pharmaceuticals, Inc.; Arcus Biosciences, Inc.; Arys; Atreca, Inc.; Bayer Corporation; Boston Biomedical Inc.; Bristol Myers Squibb; Celgene Corporation; Clovis Oncology; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Lilly; Merus N.V.; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Seattle Genetics. Research funding to Institution.Data Safety Monitoring Board for 1Globe Health Institute; AstraZeneca; Exelixis, Inc.; FibroGen, Inc.; Lilly; Merck & Co., Inc./Eisai Co., Ltd.; Pancreatic Cancer Action Network; Suzhou Kintor Pharmaceuticals, Inc.; and The Valley Hospital.Other Financial or Material Support from holding patents WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to Imugene. WO/2019/055687 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA – Licensed to Recursion.Faculty/PlannerRachna Shroff, MD, MS, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Genentech, Inc.; Incyte Corporation; Merck & Co., Inc.; QED Therapeutics; Servier Laboratories; Syros Pharmaceuticals, Inc.; and Zymeworks Inc.Grant/Research Support from Bayer; Bristol Myers Squibb; Exelixis, Inc.; IMV Inc.; Loxo Oncology, Inc.; Merck & Co., Inc.; Novocure, Inc.; NuCana; Pieris Pharmaceuticals, Inc.; QED Therapeutics; Rafael Pharmaceuticals, Inc.; Seagen; and Taiho Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GUS865. CME/MOC/AAPA/IPCE credit will be available until February 18, 2025.Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported through independent educational grants from AstraZeneca and Incyte Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerMilind Javle, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals Inc.; Array BioPharma Inc.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; BeiGene; Biocartis; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; EMD Serono Inc.; GlaxoSmithKline; Halozyme Therapeutics; Helsinn; Incyte Corporation; Ipsen; Janssen Pharmaceuticals, Inc.; Lilly; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; OncoSil Medical Ltd; QED Therapeutics, Inc.; Servier Laboratories; Taiho Oncology, Inc.; and TransThera Biosciences Co. Ltd.Faculty/PlannerTanios Bekaii-Saab, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for (to self) AbbVie; Artiva Biotherapeutics; Aptitude Health; AstraZeneca; BeiGene; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Caladrius Biosciences; Celularity Inc.; Daiichi Sankyo Co., Ltd.; Deciphera Pharmaceuticals, Inc.; Exact Sciences Corporation; Exelixis, Inc.; Foundation Medicine, Inc.; GlaxoSmithKline; Immuneering Corporation; Illumina, Inc.; Imugene Ltd.; Janssen Pharmaceuticals, Inc.; KANAPH Therapeutics Inc.; Natera, Inc.; Replimune Group Inc.; Sanofi; Sobi; Stemline Therapeutics, Inc.; Treos Bio Limited; Xilis, Inc; and Zai Lab. To institution: Arcus Biosciences, Inc.; Bayer Corporation; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; Merck KGaA; Merus; Pfizer; Seattle Genetics; and Servier Laboratories.Grant/Research Support from AbGenomics Corporation; Agios Pharmaceuticals, Inc.; Arcus Biosciences, Inc.; Arys; Atreca, Inc.; Bayer Corporation; Boston Biomedical Inc.; Bristol Myers Squibb; Celgene Corporation; Clovis Oncology; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Lilly; Merus N.V.; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Seattle Genetics. Research funding to Institution.Data Safety Monitoring Board for 1Globe Health Institute; AstraZeneca; Exelixis, Inc.; FibroGen, Inc.; Lilly; Merck & Co., Inc./Eisai Co., Ltd.; Pancreatic Cancer Action Network; Suzhou Kintor Pharmaceuticals, Inc.; and The Valley Hospital.Other Financial or Material Support from holding patents WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to Imugene. WO/2019/055687 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA – Licensed to Recursion.Faculty/PlannerRachna Shroff, MD, MS, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Genentech, Inc.; Incyte Corporation; Merck & Co., Inc.; QED Therapeutics; Servier Laboratories; Syros Pharmaceuticals, Inc.; and Zymeworks Inc.Grant/Research Support from Bayer; Bristol Myers Squibb; Exelixis, Inc.; IMV Inc.; Loxo Oncology, Inc.; Merck & Co., Inc.; Novocure, Inc.; NuCana; Pieris Pharmaceuticals, Inc.; QED Therapeutics; Rafael Pharmaceuticals, Inc.; Seagen; and Taiho Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GUS865. CME/MOC/AAPA/IPCE credit will be available until February 18, 2025.Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported through independent educational grants from AstraZeneca and Incyte Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerMilind Javle, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals Inc.; Array BioPharma Inc.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; BeiGene; Biocartis; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; EMD Serono Inc.; GlaxoSmithKline; Halozyme Therapeutics; Helsinn; Incyte Corporation; Ipsen; Janssen Pharmaceuticals, Inc.; Lilly; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; OncoSil Medical Ltd; QED Therapeutics, Inc.; Servier Laboratories; Taiho Oncology, Inc.; and TransThera Biosciences Co. Ltd.Faculty/PlannerTanios Bekaii-Saab, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for (to self) AbbVie; Artiva Biotherapeutics; Aptitude Health; AstraZeneca; BeiGene; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Caladrius Biosciences; Celularity Inc.; Daiichi Sankyo Co., Ltd.; Deciphera Pharmaceuticals, Inc.; Exact Sciences Corporation; Exelixis, Inc.; Foundation Medicine, Inc.; GlaxoSmithKline; Immuneering Corporation; Illumina, Inc.; Imugene Ltd.; Janssen Pharmaceuticals, Inc.; KANAPH Therapeutics Inc.; Natera, Inc.; Replimune Group Inc.; Sanofi; Sobi; Stemline Therapeutics, Inc.; Treos Bio Limited; Xilis, Inc; and Zai Lab. To institution: Arcus Biosciences, Inc.; Bayer Corporation; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; Merck KGaA; Merus; Pfizer; Seattle Genetics; and Servier Laboratories.Grant/Research Support from AbGenomics Corporation; Agios Pharmaceuticals, Inc.; Arcus Biosciences, Inc.; Arys; Atreca, Inc.; Bayer Corporation; Boston Biomedical Inc.; Bristol Myers Squibb; Celgene Corporation; Clovis Oncology; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Lilly; Merus N.V.; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Seattle Genetics. Research funding to Institution.Data Safety Monitoring Board for 1Globe Health Institute; AstraZeneca; Exelixis, Inc.; FibroGen, Inc.; Lilly; Merck & Co., Inc./Eisai Co., Ltd.; Pancreatic Cancer Action Network; Suzhou Kintor Pharmaceuticals, Inc.; and The Valley Hospital.Other Financial or Material Support from holding patents WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to Imugene. WO/2019/055687 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA – Licensed to Recursion.Faculty/PlannerRachna Shroff, MD, MS, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Genentech, Inc.; Incyte Corporation; Merck & Co., Inc.; QED Therapeutics; Servier Laboratories; Syros Pharmaceuticals, Inc.; and Zymeworks Inc.Grant/Research Support from Bayer; Bristol Myers Squibb; Exelixis, Inc.; IMV Inc.; Loxo Oncology, Inc.; Merck & Co., Inc.; Novocure, Inc.; NuCana; Pieris Pharmaceuticals, Inc.; QED Therapeutics; Rafael Pharmaceuticals, Inc.; Seagen; and Taiho Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Imugene Ltd (ASX:IMU) CEO Leslie Chong sits down with Jonathan Jackson in the Proactive studio to delve into the company's latest milestone - commencement of dosing for the first patient in the intravenous monotherapy arm of a Phase 1 clinical trial of the CD19 oncolytic virotherapy drug candidate, onCARlytics (also known as on-CAR-19, CF33-CD19 HOV4). Dubbed OASIS, the trial focuses on adult patients grappling with advanced or metastatic solid tumours. The trial's primary objective is to assess the safety and efficacy of two administration routes: intratumoural (IT) injection and intravenous (IV) infusion, either independently or in conjunction with blinatumomab, a CD19-targeting bispecific monoclonal antibody (marketed as Blincyto® by Amgen). The combination arm of the study will merge onCARlytics with blinatumomab, presenting a promising avenue for patients who previously found limited benefit from Blincyto® therapy alone. Imugene's groundbreaking work is garnering attention, with the company recently featured on Channel 7. #ProactiveInvestors #ImugeneLtd #ASX #biotech #onCARlytics #ClinicalTrial #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Imugene (ASX: IMU) chief executive officer and managing director Leslie Chong joins Small Caps to discuss the progress of the company's phase 1 MAST trial of its novel cancer-killing virus CF33-hNIS – known as VAXINIA. The oncolytic virus in VAXINIA has been shown to shrink colon, lung, breast, ovarian and pancreatic cancer tumours in preclinical laboratory and animal models. After obtaining promising early results from trials, Imugene is now increasing its dosage rates for a trial which is combing VAXINIA with pembrolizumab. Imugene recently reported that 38 patients had been dosed with VAXINIA during the continuing dose escalation phase. Overall, the study aims to recruit up to 100 patients across approximately 10 trial sites in the United States and Australia. Articles:https://smallcaps.com.au/imugene-novel-cancer-treatment-enters-new-phase-mast-trial/https://smallcaps.com.au/imugene-positive-outcomes-novel-virus-trial-advanced-cancers/ For more information on Imugene:https://smallcaps.com.au/stocks/asx-imu/See omnystudio.com/listener for privacy information.

Imugene Ltd (ASX: IMU) CEO Leslie Chong joins Jonathan Jackson in the Proactive studio this morning to discuss encouraging results from the company's Phase 1 Metastatic Advanced Solid Tumours trial, evaluating the safety and efficacy of its novel cancer-killing virus CF33-hNIS (VAXINIA). In exceptional news for the company, one patient with biliary tract cancer achieved a Complete Response after being treated at a mid-dose level and has remained in remission for over 430 days. Two Partial Responses were also observed in melanoma patients at a mid-dose level. Imugene will now move to a dose escalation phase. Early results were presented at the American Society of Clinical Oncology - Gastrointestinal Cancer Symposium (ASCO-GI) in San Francisco, California. Chong discusses what that means for the company and what shareholders can expect in 2024. #ProactiveInvestors #ASX #Imugene #CancerTrial #CancerTreatment #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Imugene Ltd (ASX:IMU, OTC:IUGNF) CEO Leslie Chong tells Proactive the company is preparing 10 clinical trial sites in Australia and the UK for a new PD1-Vaxx Phase 2 colorectal (CRC) cancer clinical trial set to begin in 2024. The company intends to enrol 44 patients across the six Australian and four UK sites, to participate in the study for about 18 months. The primary objective of the trial is to determine major pathological response rates, a measurement of tumour size, after treating with PD1-Vaxx but before surgery to remove any residual tumour – also known as neoadjuvant in operable CRC cancer patients. #ProactiveInvestors #ImugeneLtd #ASX #Biotech #ColorectalCancer #ClinicalTrial #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

US equities closed near the flat line, with the Dow Jones just 0.04% higher, while the S&P 500 was 0.09% lower and the Nasdaq down 0.16% lower.European major benchmarks closed higher, as regional markets regained momentum. The STOXX 600 closed 0.43% higher, with auto stocks up the most. Germany's DAX maintained gains following German inflation figures being released during afternoon trading, slowing to 2.3% in November. The DAX is now at its highest level since the beginning of August. France's CAC also closed in the green, while the FTSE 100 closed lower.What to watch today:The Australian market is set to open slightly higher, with the SPI futures suggesting a 0.1% rise at the open this morning.In commodities,Crude oil has jumped 1.65%, nearing US$78 per barrel, ahead of the OPEC+ meeting today, where the group will set its production policy for 2024. OPEC+ are considering new oil production cuts of as much as 1 million barrels a day.Meanwhile, the price of gold has rallied, hitting its highest levels in nearly seven months, off the back of a sharp decline in the US dollar. So, keep watch of ASX- listed gold miners.And iron ore is lower, trading at US$133.50 per tonne.In economic data, private sector credit data and building permit data will be out today. We'll also be awaiting eurozone inflation for October out tonight.And there's a list of companies holding their AGMs today. These include Imugene (ASX:IMU), Lake Resources (ASX:LKE), Liontown Resources (ASX:LTR) and Sayona Mining (ASX:SYA).And stocks going ex-dividend today include Aristocrat Leisure (ASX:ALL) and Technology One (ASX:TNE).Trading Ideas:Bell Potter maintains a Buy rating on EROAD (ASX:ERD) and have increased their price target by 6% to $0.95. At the stock's current share price of $0.76, this implies 25% share price growth in a year.And Trading Central have identified a bullish signal on Magellan Financial Group (ASX:MFG), indicating that the stock price may rise from the close of $7.43 to the range of $8.40 to $8.60 over 38 days, according to the standard principles of technical analysis.

Imugene Ltd (ASX:IMU, OTC:IUGNF) CEO Leslie Chong and chief medical officer Dr Paul Woodard speak with Proactive following the news it's been granted 'Fast Track' designation from the US Food and Drug Administration (FDA) for its MAST (metastatic advanced solid tumours) clinical program — evaluating the safety and efficacy of novel cancer-killing virus CF33-hNIS (VAXINIA). The FDA's Fast Track designation is awarded to help important new therapies reach patients earlier. It is designed to facilitate the development and expedite the review of drug candidates to treat serious conditions and fill an unmet medical need. #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Wall Street resumed the November rally on Tuesday with stocks closing Tuesday's session higher as comments from a Federal Reserve official boosted investor hopes that the central bank may not need to raise the interest rate any further. The Dow Jones rose 0.24%, the S&P500 added 0.1% and the tech-heavy Nasdaq rose 0.3%.US GDP Growth Rate for Q3 is out tonight and will give an indication of just how the US economy is coping during the high interest rate environment, with consensus expecting annualised growth of 5%, following a rise of 4.9% in the last reading, which provides further indication of a soft landing in the US over a recession.In Europe, markets closed mostly lower on Tuesday following the release of key economic data in the region. The STOXX600 ended Tuesday's session in the red, while Germany's DAX rose 0.16%, the French CAC fell 0.21% and, in the UK, the FTSE100 ended Tuesday's session down 0.07%. Consumer sentiment data was released in Germany and France overnight indicating German consumers are slowly increasing their willingness to buy in recession-hit Germany however income expectations in the region have declined, while in France, the French consumer remains sluggish on outlook as indicated by consumer confidence data.Locally on Tuesday, the gold miners and real estate stocks boosted the ASX to a positive finish on Tuesday, with the key index ending the day up 0.4%. The energy sector weighed on the market yesterday as oil retreated for a third straight day amid delays to the upcoming OPEC+ meeting where it is expected the group of oil producing leaders will initiate further output cuts to stabilise oil prices.For the month so far, the ASX is tracking 2.8% higher buoyed by the real estate sector as investors begin to reconsider investments in the REIT space after a heavy sell-off in this rate sensitive sector throughout the first half of 2023.The retailers took a hit on Tuesday after Australian retail sales data for October showed a decline of 0.2% which wasn't unexpected as Aussies saved money prior to the Black Friday and Cyber Monday sales periods. Economists were expecting a slight pullback in sales to a rise of 0.1% for October, however the result coming in at a 0.2% decline indicates just how hard Aussies are doing it in the high cost of living environment. We are expecting a rise in November sales though as Aussies snapped up bargains during the promotional sales weekend.What to watch today:Ahead of the local trading session here in Australia the SPI futures are expecting the ASX to open the midweek trading session up 0.28%.On the commodities front this morning, oil is trading 2.57% higher at US$76.78/barrel, gold is up 1.36% at US$2041/ounce and iron ore is down 0.74% at US$134.50/tonne.AU$1.00 is buying US$0.66, 98.16 Japanese Yen, 52.34 British Pence and NZ$1.08.Trading Ideas:Bell Potter has increased the rating on IDP Education (ASX:IEL) from a hold to a buy and increased the price target from $26.70 to $27 following the release of recent student visa data from key source markets including India, China, Vietnam, Australia, Nigeria and Thailand into key destination countries of Australia, the UK and Canada. While 1H24 is typically seasonally weaker in Australia, levels came in slightly above pre-pandemic levels and the Northern Hemisphere data was encouraging particularly for Canada which is a key market IDP operates in.And Trading Central has identified a bullish signal on Northern Star Resources (ASX:NST) following the formation of a pattern over a period of 40-days which is roughly the same amount of time the share price may rise from the close of $12.14 to the range of $14.20 to $14.70 according to standard principles of technical analysis.

General Advice Only

Imugene Ltd (ASX:IMU) CEO Leslie Chong speaks with Proactive soon after announcing the company has passed a major milestone for its Azer-cel therapy treatment with the dosing of the first patient for its Phase 1b Allogeneic CAR T Clinical Trial. It follows a Phase 1a trial that included 84 patients across leading US healthcare centres and offered strong safety and efficacy signals according to IMU. The second part of this Phase 1 trial involves the study of Azer-cel in an ongoing, multi-centre clinical trial in patients with non-Hodgkin's lymphoma blood cancer, and serves as a precursor to Phase 2 registrational (subject to FDA approval) in 2024. #ProactiveInvestors #Imugene #ASX #biotech #Azerceltherapytreatment #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Imugene Ltd (ASX:IMU) (OTCMKTS:IUGNF) CEO Leslie Chong talks Proactive through a clinical trial update of its Phase 1 MAST (Metastatic Advanced Solid Tumours) trial evaluating the safety and efficacy of novel cancer-killing virus CF33-hNIS (VAXINIA). Chong says the early positive response data being seen at the mid-dose level in hard-to-treat bile duct cancer suggests that VAXINIA may be a potent anti-cancer drug as IMU interrogates higher dose levels. #ProactiveInvestors #Imugene #ASX #biotech #VAXINIA #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

As the Federal government announces a plan to tackle cancer, one company is advancing with clinical stage immuno-oncology therapies.See omnystudio.com/listener for privacy information.

Imugene Ltd (ASX:IMU, OTC:IUGNF) CEO Leslie Chong tells Proactive the company has marked a milestone with the start of its Phase 1 clinical trial for onCARlytics, a CD19 oncolytic virotherapy drug candidate. The trial, known as OASIS (Oncolytic Assessment and Safety in Solid Tumours), represents a world-first in clinical research, combining CD19 oncolytic virotherapy with a CD19 targeting bispecific monoclonal antibody, blinatumomab (Blincyto® Amgen). The primary objective of the OASIS trial is to assess the safety and tolerability of onCARlytics (CF33-CD19) when administered intravenously or intratumorally in combination with blinatumomab. #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Imugene: A worldwide license to attack blood cancer  Listen to ASX-listed Imugene Managing Director Leslie Chong talk to Matt Birney on the Bulls N' Bears Report about Imugene's rapidly developing stable of extraordinary cancer fighting treatments that now take in blood cancers in addition to solid tumours.  See omnystudio.com/listener for privacy information.

The market has closed flat today (or up, depending on who you ask!) gaining just 0.03%. 6 of the 11 sectors saw losses, with real estate coming out on top and telco's on bottom. Imugene was down after a capital raise and investment fund Magellan was the top performer today. Next week we have profits from BHP, the biggest stock on our market and a big meeting over in the US. The content in this podcast is prepared, approved and distributed in Australia by Commonwealth Securities Limited ABN 60 067 254 399 AFSL 238814. The information does not take into account your objectives, financial situation or needs. Consider the appropriateness of the information before acting and if necessary, seek appropriate professional advice.See omnystudio.com/listener for privacy information.

The market was up on Wednesday after 3 day of losses. Only 2 of 11 sectors fell, led lower by miners. Banks were the standout for a 2nd day while energy stocks showed strong improvement. Imugene and Brainchip were the top 2 performers after both being granted US patents. Locally tomorrow, jobs data will be in focus which could impact the next interest rate decision. The content in this podcast is prepared, approved and distributed in Australia by Commonwealth Securities Limited ABN 60 067 254 399 AFSL 238814. The information does not take into account your objectives, financial situation or needs. Consider the appropriateness of the information before acting and if necessary, seek appropriate professional advice.See omnystudio.com/listener for privacy information.

It's new financial years eve and the market celebrated by finishing in the green, along with 8 of the 11 sectors. The market ended in positive territory for the week, the month, the quarter and the financial year. Downer EDI was the best performer after winning a $4.6b contract with the QLD government. Imugene rose after making progress in its cancer treatment study. Ahead, the Reserve Bank will hand down its interest rate decision on Tuesday at 2:30pm. Laura and Stevie also discuss the highlights of this financial year. The content in this podcast is prepared, approved and distributed in Australia by Commonwealth Securities Limited ABN 60 067 254 399 AFSL 238814. The information does not take into account your objectives, financial situation or needs. Consider the appropriateness of the information before acting and if necessary, seek appropriate professional advice.See omnystudio.com/listener for privacy information.

It's the start of another month and Stevie and Laura are here for your closing market update! The market took a turn and closed in the green today, along with 8 of the 11 sectors. Flower company Lynch Group lifted after raising earnings expectations due to strong demand and Imugene fell 9% despite dosing its first patient with its cancer treatment during clinical trials. Ahead, the Annual Wage Review will be in the spotlight tomorrow as this could impact the next interest rate decision. The content in this podcast is prepared, approved and distributed in Australia by Commonwealth Securities Limited ABN 60 067 254 399 AFSL 238814. The information does not take into account your objectives, financial situation or needs. Consider the appropriateness of the information before acting and if necessary, seek appropriate professional advice.See omnystudio.com/listener for privacy information.

Imugene: Cancer drug trial green lit by US FDA  Listen to ASX-listed Imugene Managing Director Leslie Chong talk to Matt Birney on the Bulls N' Bears Report about Imugene's “immunotherapy” drug that can laser-target cancerous cells in partnership with an already approved drug, potentially setting up a sublime pairing of products in the vanguard of the fight against cancer.  See omnystudio.com/listener for privacy information.

The week has come to a close, and Laura and Stevie are here to give you the updates. The ASX lifted today and finished the week up 0.3%. Tech stood out again today and 9 out of the 11 sectors were up. Coal and gold miners were worst off today and Aussie biotech company Imugene was best on the ASX today after receiving clearance from the US FDA. Finally, a look ahead to next week and find out what ASX rabbit holes the team are going down. The content in this podcast is prepared, approved and distributed in Australia by Commonwealth Securities Limited ABN 60 067 254 399 AFSL 238814. The information does not take into account your objectives, financial situation or needs. Consider the appropriateness of the information before acting and if necessary, seek appropriate professional advice.See omnystudio.com/listener for privacy information.

The Aussie share market declined this week, falling 0.5% (Mon-Thu), as the materials sector weighed down on the market the most, dropping 2.2%. Financials, consumer discretionary and utilities are also lower, while communication services and industrials advanced.   In this week's wrap, Sophia covers:(0:16) The demand outlook from the leading iron ore importing country(1:08) China's crippling property market(1:49) Bell Potter's forecast for Mineral Resources (ASX:MIN)(2:48) The best performing stocks in the ASX200(3:57) The most traded stocks & ETFs by Bell Direct clients(5:00) Four economic news items to watch out for

The Aussie share market advanced 1.46% (Mon-Thu), as investors shook off fears of a global banking crisis and digested key inflation data out of the US. Materials stocks led the charge this week with the sector rising 3.16%, buoyed by iron ore prices rising on the back of a cyclone forming off WA's Kimberley coast, a key region of iron ore export for Australia.  In this week's wrap, Grady covers: •   (0:25)  Outlook for the lithium sector •   (4:17 ) Where Bell Potter sees opportunities in lithium •   (5:11) The best performing stocks in the ASX200 •   (5:57) The most traded stocks & ETFs by Bell Direct clients •   (6:27) Two economic news items to watch out for

Imugene (ASX: IMU) managing director and chief executive officer Leslie Chong joins Small Caps to discuss the company's development of its portfolio of immunotherapies, a cancer-killing virus (VAXINIA) and other emerging technologies. Imugene is designing immunotherapies to assist a cancer patient's immune system in fighting off its malignant cells, while VAXINIA is currently being evaluated in clinical trials. Ms Chong says the company is incredibly eager to unlock the potential of its cancer-killing virus in patients across Australia and the United States where trials are being held. Articles:https://smallcaps.com.au/imugene-patent-pd1-vaxx-immunotherapy-progresses-cancer-killing-virus/ For more information on Imugene:https://smallcaps.com.au/stocks/IMU/See omnystudio.com/listener for privacy information.

The ASX rallied 0.35% today, rebounding from yesterday's rate-driven sell-off as investors piled into financial and material stocks today, while selling out of health care and consumer staples stocks.Boral (ASX:BLD) shares took flight today, adding over 12% after the building and construction materials supplier released first half results including revenue up 12% to $1.681bn, EBIT up 15% at $95.3m, NPAT increased 53% to $56.8m and adjusted EPS rose 50% to 5.1c/share. New Boral CEO Vik Bansal said RBA rate hikes haven't crimped customer demand for cement, asphalt and gravel.Suncorp (ASX:SUN) shares jumped 4.5% today after the Queensland-based financial conglomerate released first half results including group net profit up 44.3% to $560m, and cash earnings up 62.9% to $588m. The company also boosted its dividend payout to 33 cents per share, representing a 71% payout ratio of cash earnings. Group operating expenses fell 3.1% to $1.349bn, largely reflecting efficiency benefits from the strategic program of work, and the company reaffirmed its FY23 financial targets which investors have been looking for companies to share this reporting season.Strike Energy (ASX:STX) has accepted Hancock Prospecting's takeover offer of Warrego Energy for $0.40/share, over its own one-for-one scrip offer for the takeover of Warrego. Strike said despite not acquiring control of Warrego, it has achieved a number of key milestones over the last 6-months including share price appreciation of 40%, $116m in immediately available cash funding following the acceptance of Hancock's offer, and Strike's joint venture partner will be controlled by a credentialed, well-funded and motivated counterparty to pursue development activity in respect of the West Erregulla gas project.The winning stocks today were led by Boral (ASX:BLD) soaring almost 13%, Imugene (ASX:IMU) rallying 7.7% and Suncorp (ASX:SUN) climbing 4.6%.And on the losing end of the market, Elders (ASX:ELD) fell more than 5.8% after the company was sent a price query from the ASX today, while Healius (ASX:HLS) fell 5.4% and Ramelius Resources (ASX:RMS) lost 4.12% today.The most traded stocks by Bell Direct clients today were Macquarie Group (ASX:MQG), Pilbara Minerals (ASX:PLS) and Tennant Minerals (ASX:TMS).On the commodities front this afternoon, crude oil is flat at US$77.16/barrel, iron ore is down 0.8% at US$124.50/tonne and gold is up 0.13% at US$1876.33/ounce.The Aussie dollar is buying 70 US cents 91.32 Japanese Yen, 57.24 British Pence, and 1 New Zealand Dollar and 10 cents.

The local market's green run came to an end today in a muted session as the key index closed just 0.03% lower. A sharp sell-off in materials and utilities stocks offset strong gains among consumer staples and healthcare stocks today. As recession fears increasingly dominate market sentiment, sectors like consumer staples and health care are remaining resilient as these companies traditionally remain strong during a recessionary environment.Tech retail specialist JB Hi-Fi (ASX:JBH) released Q2 sales results and preliminary half year 2023 results including record sales of $5.28 billion and record earnings of $479.2 million for HY23. The strong performance follows continued elevated consumer demand and operating conditions starting to normalise following two-years of COVID related disruptions. Shares in JB Hi-Fi rallied in morning trade before retreating amid the broader market sell-off today.Hub24 (ASX:HUB) shares were sold off on Tuesday after the wealth management technology firm released a Q2 update including net inflows for the quarter broadly flat on Q1 but dropping 23.6% to $5.8 billion from record inflows achieved in Q2 of FY22, and down 13.6% for the first half of FY23.The winning stocks from today's session were Novonix (ASX:NVX) adding 5.5%, Metcash (ASX:MTS) jumping 2.74% and Johns Lyng Group (ASX:JLG) rallying 2.71%. And on the losing end of the market Imugene (ASX:IMU) tumbling 5.88%, while Capricorn Metals (ASX:CMM) and Regis Resources (ASX:RRL) each fell 5.6 and 4.8% respectively.The most traded stocks by Bell Direct clients today were ANZ (ASX:ANZ), Macquarie Group (ASX:MQG) and Telstra Group (ASX:TLS).On the commodities front, oil is trading lower again around US$79/barrel as recession fears continue dominating global market sentiment, while iron ore is also trading sharply lower by more than 4% at US$121.50/tonne as China attempts to cool demand outlook of the commodity. Gold is also down almost 0.4% today at US$1910.58/ounce and coal is only slightly lower at US$370/tonne. Goldman Sachs researchers have said commodities have the strongest outlook of any asset class in 2023 given the perfect macroeconomic environment with critically low inventories for almost every key raw material against surging demand. The year has started with a pullback in prices due to warm weather shock and rising interest rates, however with China coming back online, the yearly outlook for commodity prices is looking up.Westpac Consumer Confidence data released today showed Aussie confidence rose 5% to 84.3 points for January, which well exceeded market forecasts of a 2.3% decline.The Australian dollar is buying US$0.70, 89.75 Japanese Yen, 57 British Pence, and NZ$1.09.

The local market took lead from Wall Street today, following softer-than-expected inflation data out in America, easing investor fears of further aggressive rate hikes to come from the Fed. The ASX closed the midweek session up 0.67% buoyed by a surge in utilities stocks.Gold miner St Barbara (ASX:SBM) soared 20% today, after the company announced the successful completion of the bookbuild for the conditional placement issuing approximately 229.2m new Genesis Minerals (AXS:GMD) shares to raise $275 million to facilitate the merger of St Barbara and Genesis Minerals. Under the planned merger, St Barbara (ASX:SBM) and Genesis (ASX:GMD) will merge their Leonora District operations in WA to form a new gold company, Hoover House. St Barbara's other assets will be demerged to form a new junior gold company called Phoenician Metals which focuses on the long-term value of a portfolio including the Atlantic and Simberi operations.The winning stocks of the session were led by St Barbara (ASX:SBM) adding almost 14% at the closing bell, Block (ASX:SQ2) rallying 8.15% and Chalise Mining (ASX:CHN) adding 6.41%. And on the losing end, Imugene (ASX:IMU) tanked 5.13%, while Endeavour Group (ASX:EDV) fell 4.33% and Bendigo and Adelaide Bank (ASX:BEN) fell 3.31%.The most traded stocks by Bell Direct clients were Telstra Corporation (ASX:TLS), Arafura Rare Earths (ASX:SRU), Newcrest Mining (ASX:NCM).On the commodities front crude oil is trading 0.2% lower at US$75.22 per barrel, gold is flat at US$1,809 per ounce, and iron ore is down 2.64% at US$110.50 per tonne.Aussie dollar is buying 68 US cents, 92.65 Japanese Yen, 55.49 Japanese Yen and NZ$1.06.

Imugene Ltd (ASX:IMU) CEO Leslie Chong speaks with Proactive soon after positive new data regarding overall survival results in its HER-Vaxx HERIZON study was provided in an oral presentation at the ESMO Asia Congress 2022 in Singapore. Chong also discusses upcoming conferences and investor presentations including the JP Morgan Healthcare Conference 2023 in January in which Imugene has been invited to attend and speak. #ProactiveInvestors #Imugene #asx #biotech #ESMOAsiaCongress #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

The ASX succumbed to the pressure of the global market sell-off today, closing Tuesday's session 0.34% lower despite a morning rally. Investors sharply sold out of energy stocks amid a decline in the price of oil, while also weighing up declining consumer and business confidence data which were released today for September and October respectively. Westpac Consumer Confidence slid almost 1% for October, while NAB Business Confidence data dropped 5 points in September amid difficult business and economic conditions.The oil and gas mining giants took a hit today on the declining price of oil, with Beach Energy (ASX:BPT) falling 2.5%, Woodside Energy (ASX:WDS) shedding 2% and New Hope Corporation (ASX:NHC) ended the day down 1.2%.Despite the market closing lower, some stocks made headlines for surging ahead today including John Lyngs Group (ASX:JLG), which recovered 6% of yesterday's sharp sell-off, while Allkem (ASX:AKE) added nearly 5% and Orica (ASX:ORI) gained 4.4% today.On the losing side, Sayona Mining (ASX:SYA) was the worst performing stock on the ASX200 today despite no price sensitive news released by the lithium producer today. Imugene (ASX:IMU) continued its sell-off today, losing 5.5%, despite no news out of the company. Megaport (ASX:MP1) rounded out the bottom three performing stocks today, closing just under 5% lower. Baby retailer Baby Bunting (ASX:BBN) shares tanked more than 20% today after the company issued a warning about the company's gross profit margin as it fell 208 basis points over the PCP to 37.2%. While travel business Helloworld Travel (ASX:HLO) fell 0.5% today, despite the company releasing an update flagging a rebound in travel is imminent as its total transaction value soared 352% in the September quarter to $561m from the same period a year earlier.On the economic data front for tomorrow there is no local data released tomorrow, however overseas the UK's GDP data for August will be released tomorrow afternoon and US Producer Price Index data for September will be out later tomorrow night.The Australian dollar has weakened again, trading at 62.6 US cents, 57.19 British Pence, 91.16 Japanese Yen and 1 New Zealand dollar and 13 cents.

 The Australian market reversed early gains on Wednesday to close the midweek session 0.5% lower, as investor concerns over the RBA further tightening Australia's monetary policy were enhanced after stronger-than-expected retail sales were reported for August, up 0.6% to $34.88 billion. The higher-than-expected retail sales support the case for the RBA to raise interest rates by another 0.5% at the next meeting on Tuesday. Tech stocks took the biggest hit on Tuesday, declining 1.6% as a sector while Utilities rose almost 2%. The winning stocks for the midweek session were Coronado Global Resources (ASX:CRN), which added 5.9%, while Ramelius Resources (ASX:RMS) jumped 5.4% and Whitehaven Coal (ASX:WHC) extended its rally, adding another 3.9%. On the losing end of the market, Telix Pharmaceuticals (ASX:TLX) plunged 15.40% after the biopharmaceutical company announced a big blow to its global expansion with the company withdrawing its Marketing Authorisation Application for its Illucix drug in Europe based on regulators requesting additional Chemistry, Manufacturing and Control data which Telix says cannot be delivered within the prescribed review timeframe. Investors also sold out of Core Lithium (ASX:CXO) shares yesterday as investors may be taking profit from the company's surge of 175% over the last year.Imugene rounded out the bottom three stocks for Wednesday, ending the day down 5.3%. The most traded stocks by Bell Direct clients yesterday were the BetaShares Geared Australian Equity (Hedge Fund) (ASX:GEAR), Silver Lake Resources (ASX:SLR) and South32 (ASX:S32). Overseas, it was a positive day across most major markets following a move by the Bank of England to put a floor on UK assets overnight. The BoE is stepping in to buy $65 billion pounds of sterling bonds to stabilise the UK bond market, with investors confident that the UK government can pay back their debt, after the new government's tax cut promise triggered the biggest sell-off in decades. The FTSE100 ended the midweek session up 0.3%. Over in New York the three key indices posted strong gains on Wednesday amid the recovery in the British pound, while retail investors remain interested in Apple and Tesla shares. The Nasdaq posted the greatest gain of 2.05%, while every sector of the S&P500 closed higher with the index adding 1.97%, and the Dow Jones rallied 1.88%.Germany's DAX and the French CAC also followed suit, each adding 0.36% and 0.19% respectively. The European Union is proposing a new set of sanctions against Russia. The package would affect $7 billion Euros of Russian exports and would ban the sale of new technologies to Russia and they'd also start paving the way for an international price cap on Russian oil. What to watch today:Commodities have sharply rebounded overnight following the European Union's proposed new sanctions on Russia, with the price of Crude oil rocketing 4.31%, while Brent is up 3.21% at US$89.04 per barrel, Natural gas is 3.31% higher and gold is up almost 2% at US$1660.50 per ounce.Ahead of the local trading day, ASX futures are anticipating the market to bounce back from its red-close on Wednesday to trade sharply higher by 1.52% at the opening bell on Thursday amid boosted sentiment in markets around the world.The stocks trading ex-dividend today are Link Administration Holdings (ASX:LNK), Sigma Healthcare (ASX:SIG), and Energy One (ASX:EOL), which could be a good opportunity to buy in if you have been thinking about these stocks as stocks going ex-dividend generally trade lower on the ex-dividend date.On the economic data front, today there is no local data released however investors will be awaiting the release of US initial weekly jobless claims to gain insight into America's tight labour market. A number of Fed officials also deliver speeches today which could sway investment decisions on Thu

29 Sep 2022 - Arovella Therapeutics Limited (ASX:ALA) Managing Director and CEO Michael Baker discusses the company's collaboration with Imugene to combine therapies.

Taking a look at the markets overnight, in the US it was a choppy session that ended lower across the key indices as investor confidence slumped ahead of the release of the Fed's interest rate decision out on Wednesday US time, Thursday our time – the Dow Jones closed Tuesday's session 1.65% lower, the S&P500 lost 1.62% and the tech-heavy Nasdaq shed almost 1.5%. US housing momentum also fell for a ninth straight month in August as US mortgage rates climbed.The sell-off continued over in the UK and Europe with the FTSE100 losing 0.61% on Tuesday, while Germany's DAX fell more than 1% and the French CAC shed 1.35%.What to watch today: Locally, the RBA's meeting minutes released yesterday boosted investor confidence that the RBA is a global outlier in pushing ahead with a slower rate of interest rate hikes, a move that other central banks are not even considering yet. Investor sentiment was dampened in recent weeks after US inflation data revealed US CPI remains red hot and above market expectations, prompting the fed to likely introduce a 100 basis point or 1% rate hike on Thursday at the conclusion of the FOMC meeting.Energy, materials and utilities stocks led the market rally yesterday, with New Hope Corporation (ASX:NHC) soaring almost 9% after releasing stellar FY22 results including NPAT soaring over 1100%.Onto the commodities front, the price of commodities are down across the board today Trevor with, Crude oil trading 1.5% lower around 84 US dollars a barrel, Brent is trading, around 90 US dollars a barrel so nearly 2% lower, Iron ore is trading, 1.5% lower at 100 US dollars a tonne and Gold continues its slump, trading down 0.75% at 1663 US dollars an ounce.Ahead of the local trading session today, the ASX futures are expecting the market to open sharply lower around 1.45%, again following the global sell-off overnight.Stocks going ex-dividend today include Capitol Health (ASX:CAJ), Countplus (ASX:CUP), ADBRI (ASX:ABC), Cleanaway Waste Management (ASX:CWT) and Cochlear (ASX:COH). If you have been thinking about these stocks it might be worth considering buying in today as stocks going ex-dividend generally trade lower on the ex-dividend date.There is no local economic data news out today however investors will still be awaiting the release of the Fed's interest rate decision which is out at 4am eastern time tomorrow morning.Trading Ideas:Trading Central has identified a bullish signal on Webjet (ASX:WEB) following the formation of a pattern over a 16-day period which is the same amount of time the stock price may rise from the close of $5.43 to the range of $6.15 to $6.35, according to standard principles of technical analysis.Bell Potter has downgraded its price target on Imugene (ASX:IMU) to $0.36 per share from $0.45 and has a speculative buy rating on this stock. The price target downgrade follows Bell Potter identifying the need for the company to raise capital to support its clinical trial programs through the issuing of 400m new shares at $0.20 per share. Bell Potter also notes the company is executing quite a few trials over the next year where investors will be keeping a close eye on the results to determine just how valuable the company's biotechnology operations are.

General Advice only

The Australian market closed 0.66% higher on Friday as investor confidence extended into the final trading session of the week, after RBA Governor Philip Lowe gave dovish signs of the way forward in terms of interest rate hikes.The winning stock on Friday was Mineral Resources (ASX:MIN) after the leading mining services company said it regularly considers ‘strategic options' for its lithium segment in an indication the company may be looking to spin-off its lithium division. De Grey Mining (ASX:DEG) and Sandfire Resources (ASX:SFR) also led the gains on Friday, each adding almost 12% and 8% respectively.On the losing front, investors sharply sold-off Life360 (ASX:360) despite no price sensitive news released by the location tracking company. Imugene (ASX:IMU) also fell more than 4.2% on Friday possibly after some investors took profits from its prior session surge after the company announced it has dosed the first patient in its Phase 2 trial for its leading drug candidate HER-Vaxx.The most traded stocks by Bell Direct clients last week were Paladin Energy (ASX:PDN), Myer Holdings (ASX:MYR) and Pilbara Minerals (ASX:PLS).Over in the US, stocks rallied to end the week with strong gains. The Dow Jones added 1.2%, the S&P500 jumped 1.5% and the Nasdaq surged 2.11% on Friday. The tech-heavy Nasdaq was the winning index for the week, adding more than 4.1%. Investors bought back into shares following the end of the recent reporting season that showed companies are handling inflation and slowing growth well. Tesla shares rallied 3.6% on Friday after the EV giant said it is looking into constructing a lithium hydroxide refining facility that can help support its EV battery production. The rally carried over to Europe with the FTSE gaining 1.23%, the DAX adding 1.43% and the CAC lifting 1.41%.What to watch today:The futures are expecting the market to open 1.15% higher to extend the gains from last week into the new trading week.On the commodities front:Oil has rebounded from 8-month lows that ended last week to trade 3.21% higher at around US$86.22 a barrel.Gold is up half a percent to US$1716 an ounce.Iron ore is up just under 3%.Natural gas is trading up almost 1.5%.Economic news wise, investors will gain an insight into consumer and business confidence, with Westpac Consumer Confidence data for September out tomorrow as well as NAB Business Confidence data for August being released tomorrow. Overseas, US inflation rate data for August is also out later on Tuesday night which will give an insight into just how expensive it was to live in the US in August.Trading Ideas:Trading Central has identified a bullish signal on data software company Nuix (ASX:NXL) after identifying a pattern forming over an 87-day period, which is the same amount of time the share price is expected to rise from the close of $0.86 to the range of $1.00-$1.06 according to standard principles of technical analysis.Bell Potter has upgraded its price target on Aroa Biosurgery (ASX:ARX) from $1.35 to $1.40 and maintains its Speculative Buy rating on the stock, driven by upgrades in TELA Bio Revenues which is ARX's commercial partner.

The Australian market rebounded from last week's loss to start the trading week in positive territory, ending Monday's session up 0.34%. ASX-listed oil stocks had investors piling in today after the G-7 agreed to impose a price cap on Russian oil to reduce Russia's revenue from the key commodity used toward funding its war in Ukraine. Russia responded by saying it will stop selling oil to countries that set price caps which fuelled the rally for energy stocks today with Beach Energy (ASX:BPT) soared more than 5% during the session, while Woodside Energy (ASX:WDS) added more than 3% and Santos (ASX:STO) rallied almost 3%. The price of oil also jumped over 2% today extending gains as investors anticipate possible moved by OPEC+ producers to cut output and support prices at a meeting later today. The winning stocks for today's session were Coronado Global Resources (ASX:CRN) up 7.5%, and Whitehaven Coal (ASX:WHC) up 6.5%, as investors also piled into coal mining stocks today on the back of the price of coal soaring to a near-record high US$435 per tonne. And on the losing front, Imugene (ASX:IMU) took the biggest hit today, tumbling more than 8% despite no price sensitive news released by the biotech company today. Pointsbet Holdings (ASX:PBH) continued its decline today, shedding 6.4% and Life360 (ASX:360) was also in the firing line of investors today, with its share price closing the day down almost 5%. The most traded stocks by Bell Direct clients today were Pilbara Minerals (ASX:PLS), Whitehaven Coal (ASX:WHC), and Commonwealth Bank (ASX:CBA). Taking a look at economic data released today, ANZ job ads data for the month of August showed Australia's tight labour market continues as the number of job ads posted in the month increased 2%. In Australia at present, there are more jobs than job seekers and the latest job ads data for August is further evidence that the labour shortage crisis is far from over. Data for new vehicle sales in August was also released today, showing August was the best month for new car sales since 2017, signalling demand for vehicles continues to outweigh supply. Electric vehicle sales for the month reached a record 4.4% of all new vehicles sold. The US market will be closed overnight for the labour day national holiday. Locally, investors will be eagerly awaiting the release of the RBA's latest interest rate decision for September, which is out tomorrow.

In New York overnight, shares turned around, regaining some of the week's losses. The Dow and the S&P500 ending the first day of the month on a high note, with investors looking forward to the US jobs report for August. Meanwhile, the Nasdaq dropped 0.3%, posting a 5-day loosing streak, which was last seen for the Nasdaq in February. All three major averages however, are on track to finish the week lower. And the 2-year US Treasury yield topped 3.5%, which is the highest level since November 2007. This weighed on weigh sensitive growth stocks.What to watch today:The SPI futures are suggesting our local market will edge higher this morning, set to rise 0.29% at the open.In commodities,Crude oil has dropped almost 4%, as US recession concerns and a weakening demand outlook have overshadowed concerns over tight supply.Gold is also trading lower, hovering at its lowest in 6 weeks, pressured by the Fed's commitment in fighting inflation with aggressive policy tightening.Iron ore is also in the red, trading at levels not seen in nearly 10 months. Power cuts for Chinese manufacturers has lowered capacity for steel production and demand for steel inputs.Watch the share price movements of biotechnology company Imugene (ASX:IMU), which is set to publish its earnings results today, as well as Catalano Seafood (ASX:CSF) which is set to hold its AGM today.Trading Ideas:Bell Potter maintain their Buy rating on DGL Group (ASX:DGL). The company published its FY22 results: Underlying EBITDA was up 59% year-over-year, in-line with Bell Potter's estimates. Factoring in their expectations for FY23, the broker has lowered their price target from $3.50 to $2.15. At DGL's current share price of $1.84, this implies 16.8% share price growth in a year.Trading Central have identified a bearish signal in Regis Healthcare (ASX:REG), indicating that the stock price may fall from the close of $2.03 to the range of $1.68 to $1.74, over 10 days according to the standard principles of technical analysis.

Welcome to another episode of On the Couch with myself Henry Jennings. Today I am talking to Dr Leslie Chong, CEO and MD of Imugene (IMU).A very interesting look at an early stage biotech, where it is with trials and data, plus some words of advice on how to look at investing in biotechs in general. And a quick chat on Italian art to finish off. A great podcast and well worth a listen.Leslie has 24 years of oncology experience in Phase I – III of clinical program development, including leadership role involvement in two marketed oncology products. She was previously Senior Clinical Program Lead at Genentech, Inc., in San Francisco. Genentech is widely regarded as one of the world's most successful biotech companies with a strong oncology franchise including the best-selling breast cancer drug Herceptin.Why not sign up for a free trial? Get access to expert insights and research and become a better investor.Marcus Today DisclaimerIMPORTANTThe content included on our website, podcasts and in our emails has been prepared to provide general information only and, as such, the specific needs, investment objectives or financial situation of any particular user accessing the Marcus Today website or associated emails have not been taken into consideration. Each individual user should obtain advice from their financial planner or advisor before acting on any information provided on the Marcus Today website or associated emails so that such individual users can obtain advice applicable to their personal circumstance from their own financial advisor. Please note that stocks can go down as well as up. Past results are not indicative of future performance and returns can be negative.

Details within the Commonwealth Bank's full year results were clearly enough to bolster confidence in the broader banking sector, resulting in big gains for the majors and regional players. ANZ jumped 3.5%, Westpac 1.8% and NAB 1.6%, boosting the financial sector to a 0.5% gain. Performances elsewhere were less convincing. IT was walloped 3.8% following profit warnings from US chip manufacturers, weak earnings reports after the bell on Wall Street and news Elon Musk has been selling down his Tesla stake. Losses across healthcare, consumer discretionary and materials exceeded 1%. Telecommunications and REITs fell by 0.9% and 0.8% respectively. At the individual level, Megaport and Computershare were hammered, falling 5% apiece as analysts reacted to their earnings reports. Gold miner St Barbara delivered an update resembling a lead balloon, falling 11% to take out the title of biggest laggard. City Chic fell 7.5% on broker activity, while A2 Milk soured after failing to gain access to the lucrative US baby formula market, sliding 6.7%. Graincorp bucked the trend, lifting 5% on another profit guidance upgrade. Dare we call it a cereal offender? Imugene took out top spot, rising 6.4% as it announced new drug trials were underway. The S&P/ASX 200 eased 0.5% to close at 6993.Our top three VODs:Hoping for the best but preparing for the worstThree steady small stocksDo your homework and the opportunities will be fantastic Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.

Yesterday, our local market ended its three-day winning streak, declining 0.5% with nearly all sectors posting losses, except for the utilities and financial sector. The biggest laggard on the market was the tech sector, which follows the 1.2% tumble seen over in Wall Street for its Nasdaq index on Tuesday. The biggest gainer yesterday was Imugene (ASX:IMU), which rose 9.3% after the company provided an update on its clinical trial, which is currently in its first Phase, recruiting patients with triple negative breast cancer. Meanwhile the worst performer was St Barbara (ASX:SBM), which issued its financial year 2023 guidance, entailing higher gold production however at higher costs compared to financial year 2022. The gold miner will postpone its full-year results presentation to the 31st of August. The most traded stocks by Bell Direct clients yesterday included the BetaShares Australian Strong Bear Hedge Fund (ASX:BBOZ), Mineral Resources (ASX:MIN) and BHP Group (ASX:BHP).In the US, all three benchmarks rallied after a key inflation reading showed a better-than-expected slowdown for rising prices. The headline CPI for July lifted 8.5% year over year, whereas economists were expecting increases of 8.7%. And it was flat compared to June. So now the Fed will take this report into consideration along with other key economic data, ahead of its September meeting where it's expected to lift interest rates again. And major tech stocks outperformed the market with Netflix up 6% and Meta up 5.8%. What to watch today:Our market is expected to follow the US and open 1% higher if you go by the SPI futures. Reporting wise, some companies announcing their earnings today include AMP (ASX:AMP), Mirvac Group (ASX:MGR), QBE Insurance Group (ASX:QBE), ResMed (ASX:RMD), Arena REIT (ASX:ARF) and Telstra (ASX:TLS). In terms of forecast expectations:Citi is expecting ResMed to deliver $US827m NPAT. While consensus expects Telstra to deliver $2.085b NPAT And Mirvac Group, Citi is expecting the property developer to deliver NPAT of $615m, while consensus is less modest at $576.4m. In commodities:Oil prices were trading higher at about US$91 a barrel, following renewed gasoline demand and a cooler-than-expected inflation reading that drove investors into riskier assets.The gold price was also up, given the tame inflation report may mean the Fed may not opt for aggressive rate hikes. The spot iron ore price trades at US$111 a tonne.Rio Tinto (ASX:RIO) and SSR Mining (ASX:SSR) are set to go ex-dividend today.Online foreign exchange company OFX Group (ASX:OFX) will be holding its AGM today. Trading Ideas:Citi have decided to maintain its Sell rating on Commonwealth Bank (ASX:CBA) with a price target of $90.75. Citi believe CBA's results were in line with expectations and expect the focus to remain on the core earnings outlook where CBA has provided very little detail, instead referencing that medium term outlook on NIM, net interest margin (from Feb) is unchanged. What did other brokers think? Well Macquarie also have an Underperform rating with a less modest price target of $78. Trading Central has a bearish signal on Metcash (ASX:MTS) indicating that the stock price may fall from the close of $4.13 to the range of $3.00 - $3.20 in the next 65 days according to standard principals of technical analysis.  

Our local market closed 0.13% higher yesterday as communication services and tech stocks advanced the most. Energy stocks also rallied yesterday, following the news that OZ Minerals (ASX:OZL) rejected BHP's takeover bid. Copper and lithium stocks also gained, with Lake Resources (ASX:LKE) closing the trading session more than 15% higher. LKE was followed by Megaport (ASX:MP1), which released solid full-year results. Meanwhile, Imugene (ASX:IMU) and NAB declined the most.The major miners were the most traded stocks by Bell Direct clients. These were Lake Resources (ASX:LKE), BHP Group (ASX:BHP), Fortescue Metals (ASX:FMG) and Pilbara Minerals (ASX:PLS). In global markets, investors are trading cautiously as we wait on US inflation data. July's US consumer price index data will be released at 10:30pm AEST today. European and US equities closed lower as investors assess the potential pace of the US Fed's monetary policy tightening. The next Fed meeting isn't until September; however tonight's inflation figures will give us an indication of what to expect. In Europe, the STOXX 600 ended 0.6% lower with tech stocks leading the losses. And over in New York, the Dow Jones was down 0.2%, the S&P500 down 0.4% and the Nasdaq down 1.2%. What to watch today:The Australian market is set to fall 0.56% at the open this morning, going by the SPI futures.  In commodities, Oil is trading in the red, around US$90 per barrel, as investors weigh the potential for additional supply from Iran against the suspension of Russian oil exports. So as oil softens, watch energy producers such as Beach Energy (ASX:BPT) and Santos (ASX:STO). The price of gold however is trading higher, as investors continue to bid on the safe-haven metal as concerns around a US recession and geopolitical tensions weigh on the market. Some gold stocks to watch include Evolution Mining (ASX:EVN) and Northern Star Resources (ASX:NST). Iron ore is also higher, around US$113 a tonne. The price has rebounded after hitting its seven-month low at US$100.  Commonwealth Bank (ASX:CBA), Computershare (ASX:CPU), Dexus (ASX:DXI) and Mineral Resources (ASX:MIN) will be releasing their results today. For CBA, Citi are expecting NPAT to be $9,578 million while consensus is lower at $9,282 million. Currently, Citi have a Sell rating on CBA with a price target of $90.75, and Morgan Stanley came out yesterday with an Underweight rating and a price target of $82. And watch out for Bell Direct's coverage on CBA's results later today. Trading Ideas:Bell Potter maintain a Buy rating on Coronado Global Resources (ASX:CRN) after the company reported its half-year results yesterday. NPAT came in at US$562 million, above Bell Potter's estimate of $522 million. The company also declared an ordinary interim dividend of US 7.5cps, higher than Bell Potter's estimated US 6cps. CRN also maintained their guidance outlook, which includes a strong half in coal output. The broker increased their price target from $1.95 to $2.05, and at CRN's current share price of $1.60, this implies 28.1% share price growth in a year. Trading Central have identified a bearish signal in AGL Energy (ASX:AGL), indicating that the stock price may fall from the close of $8.47 to the range of $7.75 to $7.90 over 17 days, according to the standard principles of technical analysis. 

Life back above 7000 was short-lived, with an initial rally for the ASX200 faded throughout the day. The local bourse closed flat at 6974. IT stocks had a good day - especially stocks of a more speculative nature. Telecommunications, REITs and utilities also pushed higher. The drag on the market primarily came from the iron ore miners and energy stocks - the latter falling after a larger than expected build in US Crude Inventories drove oil prices back into the low $90 range. Consumer staples also lagged. As far as the high flyers go - Tyro Payments jumped 17%, PointsBet rose 12%, and Imugene rallied 8.7%. Punter favourite Zip Co. gave up a big early gain to close 3% lower. Orica shares flopped following the announcement of its raise to fund the acquisition of Axis Mining Technology. Grain Corp extended its decline by 6.6%. Looking ahead, the Bank of England meets tonight and is expected to raise its key bank rate by 50bp to 1.75%. In US earnings, Block, Alibaba and Warner Bros will report quarterly results. Our top three VODs:Investing for when the pandemic is overThe case for copperTo list, or not to list? That is the question See acast.com/privacy for privacy and opt-out information.

Yesterday, our local market started the new trading week with an impressive gain of 1.1%, with all eleven industry sectors closing in the green. The energy sector posted the largest gains, up 2.6%, closed followed by the real estate sector and consumer discretionary sectors, which were both up around 2% each. Looking at the ASX200 leaderboard, one of the best performers was Imugene (ASX:IMU), which lifted nearly 13% yesterday. Also performing well was coal producer New Hope Corporation (ASX:NHC) and real estate investment trust, Ingenia Communities (ASX:INA). Meanwhile, Magellan Financial Group (ASX:MFG) came under pressure, sinking 10% after its co-founder and former Chief Investment Officer, Hamish Douglass had been offloading a significant quantity of his shares in MMG. The most traded stocks by Bell Direct clients yesterday were the BetaShares Geared Australian Equity Hedge Fund (ASX:GEAR), BHP Group (ASX:BHP) and the Vanguard Australian Shares ETF (ASX:VAS). Wall Street was closed for the Independence Day holiday but in Europe the DAX fell 0.3% and the FTSE rose 0.9%, and US futures are pointing to declines tonight.What to watch today:The Australian share market is set to open flat, going by the SPI futures.Economic news wise, for the third month in a row, the RBA is all but certain to lift interest rates, with the majority of economists believing a 50 basis point increase is locked in, which would take the official cash rate to 1.35%. Stay tuned for this announcement at 2:30pm AEST. Moving to commodities, the WTI crude oil price is trading 2% higher at US$110 a barrel, as supply concerns boosted prices despite fears that a recession is looming. Gold is trading flat at US$1,809 an ounce. And the spot iron ore price trades 3.7% lower at US118 a tonne.If you hold National Australia Bank (ASX:NAB), Incitec Pivot (ASX:IPL) or CIMIC Group (ASX:CIM), you will receive your dividend payment today.Ardent Leisure Group (ASX:ALG), and Clime Capital (ASX:CAM) are set to go ex-dividend today. Trading Ideas:Citi have maintained its Buy rating on Australia's global shipbuilder, Austal (ASX:ASB) with an increased price target from $2.35 to $2.91. At its current share price of $2.38, this implies 22%. share price growth in a yearTrading Central has a bullish signal on Immutep (ASX:IMM) indicating that the stock price may rise from the close of $0.32 to the range of $0.44 - $0.46 in the next 21 days according to standard principals of technical analysis.  

Imugene: Serious inroads – a highly successful cancer drug trial Listen to ASX-listed Imugene Managing Director Leslie Chong talk to Matt Birney on the Bulls N' Bears Report about Imugene's successful clinical trial of its immunotherapy for stomach cancer that showed material increases in overall survival rates with one patient still showing promising signs over 900 days later. See omnystudio.com/listener for privacy information.

Aussie neobank Volt, which had raised tens of millions of dollars, is shutting up shop and returning deposits to customers after failing to raise funds to continue operating. Shares in ASX-listed biotech company Imugene rocketed 45% earlier this week, after it announced trial results for a new cancer treatment. The CEO and Founder of Pinterest has stepped down, handing over the reins to a Google commerce executive - and the Pinterest share price has boomed. --- Build the financial health of your team members at work with Flux at Work: https://bit.ly/fluxatwork Download the free app (App Store): http://bit.ly/FluxAppStore Download the free app (Google Play): http://bit.ly/FluxappGooglePlay --- The content in this podcast reflects the views and opinions of the hosts, and is intended for personal and not commercial use. We do not represent or endorse the accuracy or reliability of any opinion, statement or other information provided or distributed in these episodes. See omnystudio.com/listener for privacy information.

Our local market closed started the new trading week and final week of the financial year with a solid gain of 1.9%, supported by a strong rebound in bank stocks. All eleven industry sectors posted gains, with the financials, energy, tech, and consumer discretionary sectors all gaining more than 2%. Imugene (ASX:IMU) jumped a massive 46% after the company reported positive survival rates amongst advanced gastric cancer patients treated with HER-Vaxx. Also performing well were lithium stocks like Core Lithium (ASX:CXO), Liontown Resources (ASX:LTR), Lake Resources (ASX:LKE) and Allkem (ASX:AKE). While the worst performers yesterday included Evolution Mining (ASX:EVN), Northern Star Resources (ASX:NST) and Ramelius Resources (ASX:RMS).The most traded stocks by Bell Direct clients yesterday were Sims (ASX:SGM), Woolworths (ASX:WOW) and CSL (ASX:CSL). In the US, all three benchmarks started the new trading week in the red, with tech and consumer names coming under pressure, while the energy sector managed to gain 2.8%.   What to watch today:Following the negative session in the US, our local market is set to open slightly lower this morning if you go by the SPI futures.KFC owner, Collins Foods (ASX:CKF) is set to release its full year results for 2022 today. No guidance has been given, but the market will be looking for further growth after its positive first-half report.  In commodities, oil prices traded higher on the prospect of even tighter supplies, as the Group of Seven nations examine a new package of actions aimed at increasing pressure on Russia over its war in Ukraine. The gold price fell on a weaker dollar as recession fears continue. The nickel price took a hit, dropping 6.8% and the spot iron price is trading lower at US$116 a tonne.  If you hold Champion Iron (ASX:CIA) or GQG Partners (ASX:GQG), you will receive your dividend payment today.Bindi Metals will be debuting on the ASX today. It will be trading under the ticker code BIM.Trading Ideas:Citi have upgraded its rating on Iluka Resources (ASX:ILU) from a Sell to a Buy and have maintained its price target at $10.25. The upgrade is due to its share price correction and Citi's view that China's property starts are now near their low. At its current share price of $9.25, this implies 13.5% share price growth in a year.Trading Central has a bullish signal on Aristocrat Leisure (ASX:ALL) indicating that the stock price may rise from the close of $34.80 to the range of $39.75 - $40.75 in the next 43 days according to standard principals of technical analysis.  

Our local market started the new trading week in the red, extending its losses from last week, to close down 41 points, or 0.6% to 6,433. That marks seven straight days of losses for our market. The biggest laggard on the market was the energy sector, which declined 5.2%, after oil prices dropped on Friday on worries that interest rate hikes by major central banks could cut energy demand. While the major banks closed in positive territory, outperforming the broader share market.The best performing stock was Pointsbet (ASX:PBH) after the betting company secured a $94 million investment from SIG Sports. That makes the US investment firm PBH's largest shareholder. Also performing well was Pinnacle Investment Management (ASX:PNI) and bio-tech company, Imugene (ASX:IMU), both up more than 7%. Meanwhile, the worst performing stocks included lithium producers like Lake Resources (ASX:LKE), uranium miner, Paladin Energy (ASX:PDN) and coal miners like New Hope Corporation (ASX:NHC) and Whitehaven Coal (ASX:WHC).The most traded stocks by Bell Direct clients yesterday included Lake Resources (ASX:LKE), BHP Group (ASX:BHP) and Fortescue Metals (ASX:FMG). The US market was closed for the Juneteenth Federal holiday, so let's look across the sea at how European markets performed. The FTSE index lifted 1.5% as financials and energy rebounded. The German Dax closed 1.1% higher and the French CAC jumped 0.6%. What to watch today:If you go by the SPI futures, our local market is set for a positive day. The futures are up 0.7% or 45 points. Economic news wise, at 8am AEST, the RBA will be releasing to the media their review of the yield target. Following this, at 10am, Governor Phillip Lowe, will speak about inflation and monetary policy at an event in Sydney and finally, the RBA will also release the minutes from its June meeting at 11:30am. These are all important, as they may give us a sense on how aggressive the RBA will be on raising rates as well as what could happen in the next few monthsIn commodities:Oil prices edged lower on Monday, amid concerns about slowing global economic growth. Gold extended its losses as a rise in the US dollar weighed on bullion demand, with the US market holiday expected to lead to thin trading during the day. The spot iron ore price is trading down at US$125 a tonne. Peter Alexander owner, Premier Investments (ASX:PMV) and chartered accounting company Kelly Partners Group (ASX:KPG) are set to go ex-dividend today. If you hold Virgin Money UK (ASX:VUK), Coronado Global Resources (ASX:CRN) or Oceania Healthcare (ASX:OCA), you will receive your dividend payment today. Trading Ideas:Bell Potter have maintained its Buy rating on software company, Altium (ASX:ALU), however with a reduced price target, from $41.25 to $34. At its current share price of $25.49, this implies about 33% share price growth in a year.Trading Central has a bearish signal on Origin Energy (ASX:ORG) indicating that the stock price may fall from the close of $5.45 to the range of $3.60 - $4 in the next 98 days according to standard principals of technical analysis.  

The local marketed moved with less conviction than Aussie voters over the weekend; while chewing over the Federal election outcome the S&P/ASX 200 closed up a measly 0.05% to 7148.9. Materials once again supported the broader market - adding 0.8%. Codan was the stock specific winner, ending the day up 14.5% after flagging its second half profits should match its record $50 million first half success. Imugene managed to escape its recent rut after telling investors its in a strong position to round out the financial year; it finished up 12.5%. Elders galloped ahead another 8.9% thanks to a 30-40% boost to its guidance and $0.28 per share dividend. On the other side of the ballot, Polynono and Novonix shed 7.5% and 4.3% respectively. The price action reflected a slow start to the week on the data front and concern about China and COVID, but then again markets may just be warming up before the FOMC meeting minutes on Wednesday. Our top three VODs: Moody Monday on the marketsSector picks for nervous investorsPosition your portfolio for tougher times ahead: Braitling See acast.com/privacy for privacy and opt-out information.

The Aussie share market fell 0.15% this week (Mon-Thu), with industry sectors mixed. The consumer staples sector took the biggest hit, down 3.6%, while the tech sector managed to gain 0.5% after suffering major losses recently. In this week's wrap, Sophia covers:(0:48) The wage price spiral(1:50) Why biotech company Imugene (ASX:IMU) gained the most(2:39) A stock to consider if you want to buy into tech(3:03) Infomedia (ASX:IFM) jumping 29% after acquisition proposal(4:10) The most traded stocks & ETFs by Bell Direct clients(4:46) One economic news item to watch out for

Yesterday the market was up as much as 1% in the first hour of the session, following a strong trading session over on Wall Street, and soon after that the market started to drop, following weak economic data from China. China's April retail sales dropped 11.1% on the year, when the market was expecting a 6% drop, so it fell almost twice the forecast. Additionally, the unemployment rate in China rose to 6.1%. Locally, the Australian market dropped but still managed to close with a 0.25% gain. Leading the ASX200 was transport and logistics company Brambles (ASX:BXB), which gained over 11% yesterday to its highest price in 8 months. This was after news of a potential takeover offer by private equity group CVC for $20 billion. Meanwhile, Imugene (ASX:IMU), City Chic Collective (ASX:CCX), and Zip (ASX:ZIP) declined the most. Bell Direct clients were trading mostly ETFs yesterday, including VAF, VEU and EMKT. It was a volatile session overnight in the US. The Dow Jones closed with a slight gain of 0.08%, while the S&P500 dropped 0.39%. The Nasdaq was the session's underperformer, as tech stocks continue to fall, closing 1.2% lower. What to watch today:The SPI futures are suggesting the local market will rise 0.32% at the open this morning. In economic news, today we'll receive the RBA's meeting minutes, at 11:30am AEST. These are the minutes from the central bank's meeting earlier this month and it may draw some attention, as this was the meeting when the RBA lifted the cash rate. In commodities, the oil price has jumped again as concerns of tighter global supplies outweighed the weakening global demand outlook. Gold and seaborne iron ore are also trading higher. James Hardie Industries (ASX:JHX) is set to release its quarterly earnings. Trading Ideas:Citi has a Buy rating on Brambles (ASX:BXB) with a $12.29 price target. Citi say that compared to traditional leveraged buyout targets, BXB has little excess assets on its balance sheet, and CVC (who are the private equity group proposing the takeover bid) see the market as undervaluing the operating business and complex strategic initiatives over the medium term.Trading Central have identified a bearish signal in Metcash (ASX:MTS), indicating that the stock price may fall from the close of $4.63 to the range of $4.40 to $4.44 over 19 days according to the standard principles of technical analysis.

Yesterday, the Aussie share market started the new trading week extending its losses from the previous trading session. The benchmark S&P/ASX200 index slipped 1.2%, reaching its lowest level since mid-March. It comes as China intensifies its zero-COVID policy, which in turn has deepened the supply chain crisis. Looking at the sector performances, the market was broadly sold off, with both the real estate and tech sectors posting the biggest losses. The energy, consumer staples and healthcare sectors did however manage to all close slightly higher.The best performer yesterday was once again medical device company, PolyNovo (ASX:PNV), in part due to its directors toping up on PNV shares, however it also seems investors are taking advantage of its share price weakness to purchase more shares. Meanwhile, the worst performers included NOVONIX (ASX:NVX), Imugene (ASX:IMU) and Magellan Financial Group (ASX:MFG). Investors are continuing to sell Imugene shares, following the termination of its supply agreement with Merck. The most traded stocks by Bell Direct clients yesterday included Fortescue Metals Group (ASX:FMG), ANZ (ASX:ANZ) and Macquarie Group (ASX:MQG).In the US, the sell-off continued with all three benchmarks coming under pressure. The Dow Jones fell more than 600 points, the S&P500 down 3.2% and the Nasdaq slipped 4.3%. All sectors were in the red, apart from the consumer staples sector. Amid the losses, the benchmark 10-year Treasury yield hit its highest level since late 2018, trading well above 3%, which continued to crush tech names like Meta, Alphabet, Netflix, and Apple.What to watch today:If you go by the SPI futures, the market is set to open 1.39% lower.Reporting wise, capital market business, Pendal Group (ASX:PDL) will be releasing its half-year results today. Economic news wise, business confidence for April will be announced today. Business confidence currently stands at a five-month high of 16 points, however April's reading is forecasted to fall to 12 points.Moving to commodities, the oil price tumbled around 6% as China's lockdowns weigh on demand outlook. The gold price extended its decline to fall more than 1% on Monday, as the US dollar pushed to near two-decade highs. And the spot iron ore price has fallen about 4%, trading at $US136 a tonne.Private toll road developer, Atlas Arteria (ASX:ALX) is holding its AGM today.Trading Ideas:Citi have maintained its Buy rating on Domino's Pizza (ASX:DMP) with a price target of $108.42. At its current share price $67.60, this implies about 60% share price growth in a year. Trading Central has a bearish signal on Northern Star Resources (ASX:NST) indicating that the stock price may fall from the close of $9.06 to the range of $7.10 - $7.50 in the next 35 days according to standard principals of technical analysis.  

The Aussie share market came under pressure this week, as central banks started to act on taming inflation and normalising monetary conditions.   In this week's wrap, Sophia covers: (1:40) Why Imugene (ASX:IMU) tumbled(1:52) The best and worst performing stocks in the All Ords(2:11) The most traded stocks by Bell Direct clients(2:40) Big Aussie banks reporting earnings(4:20) Three economic news items to watch out for 

The not-hawkish-enough FOMC hike overnight sent a rocket up US equities, and the bulk of that enthusiasm filtered into our local market. The energy complex closed 2% higher thanks to a pop in oil. Tech also rallied 2% as bond yields eased from recent highs. Top sector was gold, closing up 3%. Top of the company pops was beaten-up Imugene, closing over 7% higher after a rough ride. In company news, NAB was thumped 1.5% lower after its update, but clawed back some losses. Bottom feeder was Janus Henderson, closing down 13% after weaker-than-expected earnings in the US overnight. All in all, the S&P/ASX200 closed at 7365, a tasty 0.8% higher, with small caps surging over 2% higher on the day.Our top three VODs: RBA rate hike impacts and top stocks to watchYour no nonsense guide on what the Fed just didBitcoin 'whales' are buying again See acast.com/privacy for privacy and opt-out information.

The major miners kicked off a solid start to the holiday-shortened week, subsequently joined by energy and gold names. The big hitters Rio and BHP both closed higher, with a weaker Australian dollar boosting exporters more broadly. It was quite the mixed bag at the top of the ladder. Imugene added 8% on no news, followed by Cleanaway closing up nearly 6%, oil and gold names thereafter featured in the top 10. Volumes were slim, it must be said. Surging bond yields in the US weighed on tech, and Aussie non-profit names copped the brunt, with Block, Xero and City Chic resting at the bottom of the ladder. The RBA Board reiterated rate hikes are coming after a few more key data reports. Markets are already fully priced for a June hike. Overall, the S&P/ASX200 reached 7565 by the close, up 0.6%.Our top three VODs: Three stocks for these challenging timesCatching up on US quarterlies so farFinding the way through Carl's Macro Micro Crypto charts See acast.com/privacy for privacy and opt-out information.

It was a case of choose your poison as to why the market closed lower today: a poor US lead, surging bond yields, commodity price drops. There was a range of company news, not all good. Pendal rejected the Perpetual bid on the basis of not being in the interest of shareholders. Iress pulled the pin on divesting its UK mortgage book. Lynas reported record sales in its update, but after a stellar run closed down 2%. Three-year highs in bond yields is the writing on the wall for the “growth at all costs” tech model. However, the bottom of the ladder was for Imugene, down nearly 9%, followed by City Chic and Z1P to round out the bottom three. It's another big week for central banks with commodity-cousins Bank of Canada and the RBNZ poised to hike by 50 basis points tomorrow. Overall, the S&P/ASX200 closed down 31 points, or 7454.Our top three VODs:Monster megacaps will continue to "distort" US marketsStocks to shelter in when the going gets roughWhat stocks will drive the Aussie market to outperform? See acast.com/privacy for privacy and opt-out information.

All sectors were down yesterday as commodity prices weakened. Long term interest rates also continued to push higher. Weighing down on the market yesterday was NAB's business confidence survey, which increased to a 5- month high, while business conditions saw the largest jump since June 2020. The rise in conditions were driven by a large increase in retail, finance, business and property. And labour costs hit a record high, further dampening sentiment. Meanwhile the 10-year government bond reached its highest level since 2015. The top performer was Regis Resources (ASX:RRL), boosted by the rise in the gold price, as well as a bullish broker note from Credit Suisse. Other gold miners also advanced, including St Barbara (ASX:SBM), Ramelius Resources (ASX:RMS), and Evolution Mining (ASX:EVN). Meanwhile, the healthcare sector declined 1.4% yesterday. Biotech company Imugene (ASX:IMU) was down the most. Bell Potter have a Speculative Buy rating on IMU. The most traded stocks by Bell Direct clients yesterday were Lake Resources (ASX:LKE), Fortescue Metals (ASX:FMG), Wesfarmers (ASX:WES), South32 (ASX:S32) and Pilbara Minerals (ASX:PLS). Overnight, the latest US inflation reading came in at its highest level since 1981. Consumer prices in March surged 8.5% from a year ago, higher than expected, and core CPI climbed 0.3% in March. The high inflation numbers raised expectations of tighter monetary policy from the Fed, which investors fear could slow the economy. The major benchmarks closed in the red. The Dow, S&P500 and Nasdaq down all down 0.3%. What to watch today:Following US equities, the SPI futures are suggesting the local market will slightly fall 0.09% at the open this morning. In commodities, the oil price has jumped almost 8%, following relief about demand in China after Shanghai eased some virus restrictions. Gold is also trading in the green, following the US inflation reading. Meanwhile seaborne iron ore is trading slightly lower. In economic data, consumer confidence data will be released today by Westpac at 10:30am AEST.Iluka Resources (ASX:ILU) will hold its AGM today.Trading Ideas:Bell Potter have maintained its Buy rating on capital market company, Pendal Group (ASX:PDL) but have reduced its price target from $7.48 to $6.80. This comes as the Pendal board has decided the proposal from Perpetual (PPT) is not in the best interests of shareholders, as it significantly undervalues the current and future value of the business. Now PDL closed 0.19% lower yesterday to $5.29, which implies about 29% share price growth in a year.Trading Central has a bearish signal on Santos (ASX:STO) indicating that the stock price may fall from the close of $8.00 to the range of $6.70 - $6.90 in the next 26 days according to standard principals of technical analysis.

This episode of Equity Mates is in partnership with ASX CEO Connect, which brings together listed companies and retail investors. Hosted virtually by the ASX every second month, it is a great opportunity for you to hear from CEOs and leaders of some of the most popular companies on the ASX from the comfort of your own home, for free.Go to the CEO Connect page on the ASX website to find out more and register your interest for upcoming events.Throughout this year, Equity Mates will bring you 6 interviews with some of the key CEOs from these events for you to hear more about their business vision, strategy & latest achievements. Today, we speak to Dr Leslie Chong.Dr Chong is the CEO and Managing Director of Imugene, an ASX-listed biotechnology company working to change the paradigm of cancer treatment - trading under the ASX ticker IMU. Dr Chong has over 20 years experience in leading clinical and department development in oncology including at major pharmaceutical companies Genentech, GSK and Roche.*****Calling all bulls, bears and party animals. The market's closed and the bar is open. Come and trade ideas at Australia's biggest investing festival - Equity Mates' FinFest.With expert speakers and guests, DJs and booze, it's an inspiring and empowering event for investors of any level of experience.Save the date - 15th October, 2022 Sydney - Head to equitymates.com/finfest to register your interest.Equity Mates' FinFest, powered by Stake*****In the spirit of reconciliation, Equity Mates Media and the hosts of Equity Mates Investing Podcast acknowledge the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respects to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander people today. *****Equity Mates Investing Podcast is a product of Equity Mates Media.All information in this podcast is for education and entertainment purposes only. Equity Mates gives listeners access to information and educational content provided by a range of financial services professionals. It is not intended as a substitute for professional finance, legal or tax advice. The hosts of Equity Mates Investing Podcast are not financial professionals and are not aware of your personal financial circumstances. Equity Mates Media does not operate under an Australian financial services licence and relies on the exemption available under the Corporations Act 2001 (Cth) in respect of any information or advice given.Before making any financial decisions you should read the Product Disclosure Statement and, if necessary, consult a licensed financial professional. Do not take financial advice from a podcast or video. For more information head to the disclaimer page on the Equity Mates website where you can find ASIC resources and find a registered financial professional near you. Equity Mates is part of the Acast Creator Network. See acast.com/privacy for privacy and opt-out information.

It was a powerhouse for the contrarian trade with the froth blown off the resources sector and the goldies, while tech caught a tailwind. A late contender for the top of the ladder was Uniti, closing up nearly 11% on a Macquarie consortium bid at the 11th hour. Up until then, med-tech Imugene was comfortably in the lead after announcing a green light for a trial, closing up nearly 10%. With a somewhat irrational trust in the Fed, growth stocks soared, led by poster-children Block and Zip, both closing up over 7%. A profit downgrade and nasty supply side costs saw Fisher and Paykel Health lose nearly 8% and was pretty lonely amongst the losers. In contrast to yesterday's blue chip rally, today was about small caps jumping by 1.1%, as overall the S&P/ASX200 closed up 37 points or 0.5%.Top Three VODs:The three inflation waves set to shake up you portfolioHome ground advantage; why Milford's long Australia and New ZealandThree small caps for rising rates | Neuren Pharma | TYMLEZ See acast.com/privacy for privacy and opt-out information.

Another day and another choppy trading session, continuing what was a largely upbeat, but volatile week. Today, resources and energy were on investors' shopping list. Strange bedfellows Block, Imugene and Paladin were at the top of the ladder, closing at least 7% higher on the day, but the thematic was outperformance across miners and energy stocks. In contrast, Megaport sat at the bottom of the ladder all day, and closed down nearly 8%. Other laggards such as Star and Eagers Automotive were company specific with no strong theme. Overall, the S&P/ASX200 added 30 points or 0.4%, capping a solid week of gains, the strongest week in over a year.Our top three VODs of the day:Sage Capital's two stocks for two uncertain themesA BHS to protect your portfolio from rising ratesFour of the ASX's "fallen angels" See acast.com/privacy for privacy and opt-out information.

Access additional Imugene interviews and updates at https://b2binterviews.com/imugene .

Leslie Chong is the MD & CEO of Imugene, an ASX listed immune-oncology company. Since she joined the company in 2015 its valuation has increased from $12 million to $1.8 billion. This is quite an achievement for a company that has less than 10 full time employees. Leslie and her team work in a very stressful environment, so she is aware of the importance of looking after their mental health. Leslie is a big believer in random acts of kindness. From sending gifts to her team, to calling shareholders to answer their questions personally. Hosted on Acast. See acast.com/privacy for more information.

Yesterday, the Aussie share market managed to claw back some of its losses from Friday, gaining 0.37%. Leading the gains were oil and gold stocks, following escalating fears of a Russian invasion of Ukraine. Looking at the sector performances, only six out of 11 sectors closed higher. The energy sector gained the most, up over 3%, while the healthcare sector declined 1.4%.  Gold miners dominated the leaderboard, including Regis Resources (ASX:RRL), Evolution Mining (ASX:EVN), and Northern Star Resources (ASX:NST). The best performing stock on the ASX200 was Beach Energy (ASX:BPT), up an impressive 9.4%, after the company reported a solid first-half result, which included a 26% increase in EBITDA to $513 million. Meanwhile, the worst performing stocks were NOVONIX (ASX:NVX), Imugene (ASX:IMU) and Liontown Resources (ASX:LTR), all falling over 7%. The most traded stock by Bell Direct clients yesterday was JB Hi-Fi (ASX:JBH). The company released strong half-results yesterday, and announced a $250m share buyback, which sent its share price up 5.4%. Bell Potter maintain their HOLD rating on the stock but have increased its price target to $51.85, from $49.60.In the US, all three benchmarks closed lower, as investors evaluate concerns about the Fed's next plan for interest rate hikes, as well as the tensions between Russia and Ukraine. And earnings results are expected to ramp up again this week, with Nvidia, Walmart, Shopify and more scheduled to report.Following the negative session on Wall Street, the futures are suggesting the Aussie share market will open 0.9% lower this morning. What to watch today:In economic news, the RBA will release its meeting minutes for February. The RBA is currently relatively dovish on rate hikes as local inflation is not as out of control as in the other major economies. Reporting season: It's a big week of results and today, the biggest company on the ASX, BHP Group (ASX:BHP) will release its half-year results. Stay tuned for our separate video where we'll take you through the highlights. Some other companies reporting today include Ansell (ASX:ANN), Dexus (ASX:DXS), Sims (ASX:SGM), Adore Beauty (ASX:ABY), Elmo Software (ASX:ELO) and Seek (ASX:SEK).Computershare (ASX:CPU) is set to go ex-dividend today. In commodities, the oil price hit 7-year highs, boosted by Russia and Ukraine's tensions. The oil price is currently trading at about US$95 a barrel. And in a similar tale, the gold price also gained and is trading about 0.6% higher to US$1,872 an ounce. The lithium, palladium and silver price are all trading higher, while the seaborne iron ore price is trading 0.5% lower to US$150 a tonne. Trading Ideas:Bell Potter have maintained its BUY recommendation on Mineral Resources (ASX:MIN) and have increased its price target by a modest 20% to $61.35. Bell Potter believe MIN's recent financial results were significantly impacted by the large decline in realised iron ore prices, however highlighted that the business made strong progress in the quarter towards its strategic goals, including expanding its iron ore export capacity, evolving its iron ore business to a low-cost base that will make it resilient to low iron ore price environments, and lastly, MIN's ability to capture the downstream margins in its lithium business. As for other broker's ratings on MIN, Macquarie have an Outperform rating with a $70 price target, while Ord Minnett have a SELL rating and $45 price target. Trading Central has a bullish signal on Westgold Resources (ASX:WGX). This signal indicates that the stock price may rise from the close of $2.03 to the range of $2.29 -$2.35 in the next 40 days, according to standard principles of technical analysis. 

After broad selling across the market as the US Fed signalled rate rises, the local market rebounded on Friday, ending the week on a positive note. The market was boosted by positive earnings results in the US, with Atlassian and Apple providing strong quarterly earnings. The ASX closed over 2% higher, with Imugene (ASX:IMU) in the lead. The biotech company gained 10.5% to $31.50, after announcing a new supply agreement with Swiss pharmaceutical company Roche. Meanwhile, gold miners were among the worst performers on Friday, as the price of gold dropped below US$1,800 an ounce. Ramelius Resources (ASX:RMS) fell to a 4-month low, down 8%, while Newcrest Mining (ASX:NCM) fell 6.4%. Both companies also reported quarterly results on Friday. The most traded stocks by Bell Direct clients on Friday included BHP (ASX:BHP) and Rio Tinto (ASX:RIO) as the price of iron ore edged higher, in preparation for an increase in demand following the Beijing Winter Olympics. European stocks saw their fourth straight week of losses, while US equities ended the week with gains. The Dow had its best day of 2022, up 1.65%. The S&P500 added 2.4% and Wall Street also saw a tech-led rally, with the Nasdaq gaining over 3%. Despite the rally on Wall Street, the SPI futures are suggesting the ASX200 will drop 0.23% at the open this morning. What to watch today:Oil is trading above US$87 a barrel, supported by fears of supply disruptions due to geopolitical risks in Ukraine. Additionally, the market is awaiting OPEC's meeting next week. So watch energy producers Woodside Petroleum (ASX:WPL) and Santos (ASX:STO). The gold price has dropped below US$1,800 an ounce as the dollar and treasury yields jumped following the Fed's hawkish updates. The seaborne iron ore price is higher, trading above US$130 a tonne. Pilbara Minerals (ASX:PLS) will release their second quarter update today. We will be looking at whether the company achieved its shipment guidance, as well as pricing with reports of record lithium price levels.Gold Road Resources (ASX:GOR) will release its quarterly production report and IGO (ASX:IGO) will release its earnings result. Trading Ideas:Bell Potter maintain their BUY rating on National Australia Bank (ASX:NAB) with a $31 price target. NAB last closed at $27.25, implying 13.8% share price growth in a year. Trading Central have identified a bullish signal in Breville (ASX:BRG), indicating that the stock price may rise from the close of $27.52 to the range of $32.75 - $34.00. The pattern formed over 18 days which is roughly the period in which the target price range may be achieved, according to standard principles of technical analysis.

The local sharemarket ended the shortened and volatile trading week on a strong note, more than erasing yesterday's steep losses. The S&P/ASX200 ended up close to 2.2% higher, but failed to make it back above the 7000 level. The blue-chips led the market higher with all sectors finishing in the green, led by consumer discretionary and staples. Wesfarmers, Coles and Macquarie Group among the leaders, while the goldminers again suffered with Newcrest falling more than 6%, disappointing the market with its quarterly update. Biotech shares shone with Imugene soaring after announcing a supply deal with drugmaker Roche, while Polynovo and Clinuvel also jumped. Australian tech stocks continue to mirror their US counterparts in the face of a more aggressive stance from central banks in fighting inflation.Our top three VODs:Going back to basics for this buy, hold and sellHas Australia overreacted to the global equities selloff?Bored Apes | nouns and the Australian Open - the world of NFTs See acast.com/privacy for privacy and opt-out information.

Yesterday, the ASX200 closed 0.5% lower to 7,139 points, and it was the technology, utilities and mining stocks that were hit the hardest. On the flip side, the real estate sector managed to post a 1.45% gain. The best performing stock was Uniti Group (ASX:UWL), up an impressive 9.3% after it was revealed that multiple approaches have been made towards the company, suggesting an interest in acquiring UWL. Goodman Group (ASX:GMG) was also on the rise, closing 3.5% higher following a broker note out from Macquarie. The broker expects that GMG could upgrade its FY2022 guidance in its half-year results, set to be released on the 17th of February. Macquarie has an Outperform rating and an increased price target to $26.63. Meanwhile Regis Resources (ASX:RRL) led the losses, falling 14.3% after cutting its full-year production guidance because of a geotechnical incident at its Rosemont mine and other operational challenges. Other stocks coming under pressure included Imugene (ASX:IMU), Life360 (ASX:360), and Liontown Resources (ASX:LTR).In the US, it was a very choppy session, with the Dow plunging over 1,000 points during the session, however managed to make a remarkable comeback to close in the green, up 0.29%. The S&P500 lifted 0.28% and the Nasdaq up 0.63%. Investors began the session dumping tech shares, as they have all month, however those shares rebounded as the day went on with Meta, Amazon and Microsoft closing higher. And it's expected on Wednesday that the Fed will signal its plans on when it will raise rates, after its two-day meeting.Now, despite the comeback in the US, the futures are suggesting the Aussie share market will open 1.30% lower this morning. What to watch today:Q4 production reports will be released by Beach Energy (ASX:BPT), Fortescue Metals (ASX:FMG), Iluka Resources (ASX:ILU), Mineral Resources (ASX:MIN) and St Barbara (ASX:SBM).The latest consumer inflation report is out this morning. A high reading could force the RBA to raise interest rates earlier. Also out today, is Business Confidence for December. The oil price fell 1.5% off the back of a stronger dollar and concerns over the possibility of quicker than expected increases to interest rates by the Fed.While the gold price gained 0.6% to US$1,843 per ounce as Ukraine tensions boost the safe-haven's appeal.The spot iron ore price traded flat at US$133 a tonne. Paradigm Biopharmaceuticals (ASX:PAR) is holding its AGM today.Trading Ideas:Bell Potter has maintained its BUY recommendation on Australia's largest horticultural company, Costa Group (ASX:CGC) with a price target of $3.85. CGC closed 1.7% higher yesterday to $2.94, which implies 31% share price growth in a year. Trading Central has a bullish signal on Straker Translations (ASX:STG). This signal indicates that the stock price may rise from the close of $1.50 to the range of $1.78 - $1.86 in the next 24 days, according to standard principles of technical analysis. 

The local market closed 0.1% lower yesterday. While materials lead the market, the healthcare sector declined the most. Biotech company Imugene (ASX:IMU) rallied 7%, closely followed by JB Hi-Fi (ASX:JBH), who reported a better-than-expected first-half trading update. Total sales managed to rise, while net profit fell 9.5%. JBH closed yesterday at $49.84 and Bell Potter maintain their HOLD rating on the stock, while Morgans upgraded from a HOLD to an ADD. Pointsbet (ASX:PBH), Virgin Money (ASX:VUK) and Zip (ASX:Z1P) were among the worst performers yesterday. Some of the most traded stocks by Bell Direct client yesterday included Lake Resources (ASX:LKE), APA Group (ASX:APA) and BrainChip (ASX:BRN). European stocks closed lower as investors reacted to developments in the oil and bond markets. Oil and gas shares gained the most, off the back of a surge in oil prices amid rising tensions in the Middle East. And global markets have been watching the Fed, as they're expected to hike interest rates and tighten monetary policy. And as US bond yields rose on Tuesday, the tech sector suffered. The Nasdaq down 2.3%, its lowest level in 3-months and down 10% from its most recent high. The Dow was down 1.4% and the S&P500 down 1.7%. The US market was weighed down by Goldman Sachs shares, which dropped 7% after the bank reported fourth-quarter earnings which missed analyst expectations. Meanwhile, the 10-year yield rose to a 2-year high. Following New York, the SPI futures are suggesting the local market will fall 1.04% at the open. What to watch today:Oil is trading higher at US$86 a barrel, boosted by tight supply and geopolitical tensions in the Middle East. Gold is trading slightly lower at US$1,813, easing from recent highs after the 10-year Treasury yield rose to pre-pandemic highs this week. The seaborne iron ore price is trading 1.2% higher at US$127 a tonne. Economic data to look out for today is the consumer confidence index for January, which will be released at 9:30am this morning. It's expected to decline amid concerns of the rapidly spreading Omicron variant. BHP (ASX:BHP), Lynas Rare Earths (ASX:LYC) and Woodside Petroleum (ASX:WPL) are set to release their fourth quarter production reports today. Alternative Investment Trust (ASX:AIQ), Kelly Partners Group (ASX:KPG), and Plato Income Maximiser (ASX:PL8) and set to go ex-dividend today.Trading Ideas:Bell Potter maintain their BUY rating on Life360 (ASX:360) and have decreased their price target from $16.25 to $15. Next Thursday Life360 will report and Bell Potter expect the company to have achieved all key 2021 guidance metric. Trading Central have identified a bullish signal in NOVONIX (ASX:NVX). This bullish signal indicates that the stock price may rise from the close of $10.21 to the range of $14.50 - $15.50. The pattern formed over 34 days which is roughly the period of time in which the target price range may be achieved, according to standard principles of technical analysis.

Top of the pops was JB Hi-Fi with early metrics outpacing analyst estimates, the share price closing up 7%. The update from Data#3 was a beat compared with October guidance, and it closed up over 13%. At the other end a big miss in Redbubble's update, the share price slashed by over 20%. As the EV wave consumes 2022, Liontown added 6% (Henry Jenning's buy today,) a beacon for the in-demand lithium sector. Cancer drug company Imugene gained 7% on a broker upgrade. The slump in weekly ANZ consumer confidence was eye-watering, let's hope an upbeat employment report later in the week stems the bleeding. Today's price action on the whole was firmly in the directionless basket, the ASX200 closing down 8 points or 0.1%.Our top three VODs: What 'a kettle of hawks' means for stocksThe uranium supercycle is not over yetA decade of opportunities: Monik Kotecha's two big tech big buys See acast.com/privacy for privacy and opt-out information.

To access the full interview, visit www.b2binterviews.com/imugene .

Imugene – Could this partnership stop cancer in its tracks? Listen to ASX-listed Imugene Managing Director Leslie Chong talk to Matt Birney on the Bulls N' Bears Report about Imugene's new cancer fighting partnership that looks like it is a match made in heaven. See omnystudio.com/listener for privacy information.

The Aussie share market hit a record high last Friday closing at 7,179 points, beating the record set back in February 2020. Today, the Aussie share market is set to follow Wall Street's lead with the futures suggesting the market will lift 0.08% to 7,181. Melbourne's virus outbreak could cast a shadow however. What to watch:Economic news out this week: RBA meeting tomorrow, economic growth for the quarter will be released on Wednesday and on Thursday the balance of trade, that's Australian imports vs. exports data is out for April. The most traded stocks by Bell Direct clients last Friday were: TechnologyOne (ASX:TNE), Imugene (ASX:IMU) and Rio Tinto (ASX:RIO).Oil prices fell slightly on Friday, but closed higher for the week following strong US economic data and expectations of a demand rebound.The Gold price rose 0.38%, popping above US$1,900 per ounce. This comes as US consumer prices surged in April and boosted its appeal as an inflation hedge.  Trading ideas:Bell Potter have reiterated their BUY recommendation on funeral homes and cemetery operator InvoCare (ASX:IVC) with a reduced price target of $12.20 (previously $12.80). IVC closed about 3% higher on Friday to $10.55, which implies 16% share price growth. Bell Potter has maintained their BUY recommendation on integrated poultry producer Ingham's Group (ASX:ING), with a price target of $4.30. Kina Securities (ASX:KSL), Premier Investments (ASX:PMV) and Brainchip (ASX:BRN) are all giving off bullish charting signals according to Trading Central.  

Listen to ASX-listed Imugene MD, Leslie Chong talk to Matt Birney on the 6PR Bulls N' Bears Report about the company's new worldwide license to develop and commercialise an innovative treatment for solid cancerous tumours developed by a renowned US cancer research centre. See omnystudio.com/listener for privacy information.

Listen to ASX-listed Imugene Managing Director, Leslie Chong talk to Matt Birney on the 6PR Bulls N' Bears Report about the company's cancer-fighting clinical trials that caused its market cap to jump from $12m to nearly a billion dollars. See omnystudio.com/listener for privacy information.

The Aussie share market is set to start the week higher. The futures are suggesting a gain of 0.1% which will rub out Friday's fall.  US equities closed at new records at the weekend with almost half of the US population receiving their first vaccine. What to watch today:Vaccine news – Pressure has been put on ScoMo for when Australians will receive their first dose. Economic news: New home sales data, Business and Consumer Confidence data and on Thursday, employment data is released for March. Quarterly balances will be taking place - investors and fund managers will be buying heavily back into stocks that are depressed – like tech – given bond yields have eased from their year high.  Stocks that closed in bullish breakouts and made sizeable gains last week: EML Payments (ASX:EML), Afterpay (ASX:APT) and Imugene (ASX:IMU).  Iron ore stocks will be back in focus as one of the most traded stocks across our entire business last week was BHP. The most traded stocks from Friday for our active trader desk, Bell Direct Advantage. They were Oneview Healthcare (ASX:ONE) Greenland Minerals (ASX:GGG) & 88 Energy (ASX:88E). Trading ideas:Immutep (ASX:IMM) was re-stamped as a Speculative Buy with an increased price target of $0.85 after the US FDA fast tracked its lead drug as a treatment for head and neck cancer.Whitehaven Coal (ASX:WHC) had its Buy rating increased, with Bell Potter raising its target to $2.35 as the thermal coal price strengthened in the March quarter.Gascoyne (ASX:GCY), Pact Group (ASX:PGH) and Proteomics International (ASX:PIQ) are all giving off bullish charting signals according to Trading Central.